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1. Introduction 
1.1. Allogeneic transplantation of hematopoietic stem cells 
The era of hematopoietic stem cell transplantation began in the wake of the first atomic bomb 
explosions, with landmark observations that mice could be protected from lethal effects of 
ionizing radiation on bone marrow by shielding their spleens with lead.
1
 A short time later, 
scientists showed that protection against radiation could also be conferred by intravenous 
infusions of bone marrow of healthy animals
2,3
. Later studies in the mid 1950s confirmed that 
radiation protection of bone marrow was due to transplanted stem cells.
4,5
 However, it was not 
until late 1960s that allogeneic hematopoietic stem cell transplantation was successfully used 
in human patients with immunodeficiencies
6,7
 and aplastic anemia.
8
 For patients with 
hematological malignancies, the initial underlying therapeutic principle was to treat them with 
escalating therapeutic radiation doses to levels that kill malignant cells but also cause 
irreversible bone-marrow toxicity, and then to rescue the patients’ bone marrow with 
infusions of haematopoietic stem cells from healthy donors. Analyses of preclinical data, 
however, revealed a second powerful therapeutic effect of this approach - the antileukemic 
potential of transplanted hematopoietic cells. Barnes and colleagues were the first to report 
the graft-versus-tumor (GVT) effect.
9,10
 This finding launched bone marrow transplantation in 
human leukemia patients and first results on a larger number of patients were reported in 
1977.
11
 
Since then, allogeneic transplantation of hematopoietic stem cells has evolved into an 
effective therapy for a variety of hematological and non-hematological malignancies. The 
treatment goal in non-hematological malignancies as in immunodeficiencies or bone marrow 
aplasia is to exchange inadequate hematopoesis with one derived from a healthy donor. In the 
treatment of hematological malignancies, high intensity myeloablative therapy (high-dose 
cytotoxic chemotherapy and irradiation) eradicates malignant cells and the infusion of donor 
stem cells enables reconstitution of the hematopoietic system in the recipient, but also shows 
an anti-leukemic effect (GVL; graft-versus-leukemia effect), mediated by donor T-
lymphocytes present in the graft. The number of allogeneic transplantations continues to 
increase with more than 25 000 performed annualy. However, the main limitation of treating 
broader spectrum of diseases and patients with allogeneic stem cell transplantation is graft-
versus-host disease (GVHD), a reaction closely associated to GVL effect. 
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1.1.1. Histocompatibility 
Both GVHD and GVL occur when donor T lymphocytes respond to genetically defined 
proteins on host cells. The most important proteins are Human Leukocyte Antigens (HLA), 
which are highly polymorphic and are encoded by the major histocompatibility complex 
(MHC) genes, located on short arm of chromosome 6. Class I HLA (A, B, and C) proteins are 
expressed on almost all nucleated cells of the body and present antigenes to CD8+ 
lymphocytes.
12
 Class II proteins (DR, DQ, and DP) are primarily expressed on hematopoietic 
cells (B cells, dendritic cells, monocytes), but their expression can be induced on many other 
cell types following inflammation or injury and they present antigenes to CD4+ 
lymphocytes.
13
 
Beside major histocompatibility antigens, there are also “minor” histocompatibility antigens 
(mHA), which lie outside the HLA loci and represent host antigens also recognized as 
“foreign“ by donor T-lymphocytes. These antigens are responsible for inducing GVHD in 
HLA-identical donor and recipient.
14
 Some minor HAs are expressed on all tissues and are 
targets for both GVHD and GVL
15
, while other minor HAs, are expressed most abundantly on 
hematopoietic cells (including leukemic cells) and may therefore induce a greater GVL effect 
with less GVHD.
15,16
 
The donor and recipient can be both HLA and mHA identical only if they are identical twins 
in so-called syngenic transplantation. In this type of transplantation recipients do not develop 
GVHD. However, even from early murine studies it has been shown that leukemia-bearing  
recipients given syngeneic grafts had worse survivals and lower leukemic cure rates than 
recipients of allogeneic grafts, probably due to lack of GVL effect as well. In allogeneic 
transplantation the donor and recipient can be identical in major histocompatibility antigens 
but they are always different in minor histocompatibility antigens, especially for unrelated 
donors. Sibling donors may have some mHA compatibility. 
High-resolution DNA typing of HLA with polymerase chain reaction (PCR)-based techniques 
have now largely replaced earlier methods. However, the routine method for typing mHA is 
still not used. When typing a sibling donor it is enough to have a 6/6 match. HLA-genes are 
inherited as haplotypes and by typing six loci (HLA-A, -B and DR) it is possible to evaluate if 
a sibling is HLA-identical. When typing an unrelated donor, it is necessary to have a 10/10 
match (HLA-A, -B, -C, -DRB1, -DQB1). The incidence of GVHD is directly related to degree 
of mismatch, thus ideally donors and recipients are fully matched. However, with new 
improvements in immunosupressive treatment, a mismatched allogeneic transplantation (with 
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one or two mismatches) has become feasible as well as the use of an haploidentical donor 
(mother, father, son, daughter, brother or a sister). 
1.1.2. Graft-versus-host disease (GVHD) 
Even early experiments on mouse models showed that transplantation of bone marrow from 
different mouse strain caused „runting“ syndrome in transplanted mice.9,17 GVHD was 
described soon after initial attempts of translating allogeneic transplantation from mouse 
models to clinic. It has been more than 15 years to first successful transplantation in human 
because the graft was either rejected by the recipient, and, if accepted, patients developed 
severe fatal GVHD. GVHD is an immune reaction which develops when immunologically 
competent donor T-cells recognize MHC antigens on host antigen-presenting cells and 
activate the immune response.  
A major improvement in patient survival was made when the antimetabolite methotrexate was 
combined with the T-cell activation inhibitors cyclosporine or tacrolimus for GVHD 
prevention. 
18-20
 The same therapy is still widely used as most effective prophylactic 
treatment. However, GVHD continues to be a major source of morbidity and mortality 
following allogeneic stem cell transplantation. 
Clinically, GVHD is separated into acute and chronic GVHD. Based on an early Seattle 
experience, acute GVHD was defined to occur prior to day 100, whereas chronic GVHD 
occurred after that time.
21-23
 This definition is far from satisfactory, and a recent National 
Institutes of Health classification includes late-onset acute GVHD (after day 100) and an 
overlap syndrome with features of both acute and chronic GVHD.
24 
 The incidence of acute 
GVHD is directly related to the degree of mismatch between HLA proteins and ranges from 
35-45% in recipients of full matched sibling donor graft to 60-80% in recipients of one-
antigen HLA mismatched unrelated donor grafts.
25,26
 The incidence of the severity of acute 
GVHD is determined by the extent of involvement of three principal target organs (skin, 
gastrointestinal tract and liver). The overall grades are classified as I (mild), II (moderate), III 
(severe) and IV (very severe). Severe and very severe GVHD occurs in 15% of patients and 
carries a poor prognosis, with 25% long term survival for grade III and 5% for grade IV.
27
 
Steroids, with their potent antilymphocyte and anti-inflammatory activity, are the gold 
standard for treatment of GVHD. Upon diagnosis of  grades II to IV acute GVHD, all patients 
are primarily treated with methylprednisolone (2 mg/kg per day). 
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Chronic GVHD is the major cause of late non-relapse death following allogeneic stem cell 
transplantation.
28
 Its presentation may be progressive (active or acute GVHD merging into 
chronic), quiescent (acute GVHD that resolves completely but is later followed by chronic 
GVHD) or it may occur de novo.
29
 Older recipient age and history of acute GVHD are the 
greatest risk factors for chronic GVHD
30
, and strategies to prevent acute GVHD may 
therefore help to prevent chronic GVHD. The manifestations of chronic GVHD are somewhat 
protean, and are often of an autoimmune nature. Clinical signs often first appear in the buccal 
mucosa and historically chronic GVHD was evaluated as limited or extensive. Recently, new 
consensus criteria for the diagnosis and staging of chronic GVHD have been developed.
24 
The 
use of corticosteroids (with or without a calcineurin inhibitor) is the standard of care, and on 
diagnosis of extensive GVHD, all patients are primarily treated with methylprednisolone (1 
mg/kg per day). 
1.1.3. Pathophysiology of GVHD 
The basic principles necessary for the development of GVHD were initially described by 
Billingham in 1966: GVHD requires that (i) the graft must contain immunocompetent cells, 
(ii) the host must be incapable of rejecting the graft the, and (iii) there must be 
incompatibilities in transplantation. 
31
 More recently, it has been defined that mature donor T 
cells are essential immunocompetent cells necessary for the induction and pathogenesis of 
acute GVHD, suggesting that GVHD is a T cell-mediated inflammatory disease, 
32
 and that T 
cell number in the transplant correlates with GVHD severity.
33
 The second condition of host 
incapability to reject the graft is usually met after a patient receives myeloablative 
chemotherapy or anti-thymocyte globuline. Third condition is always met, except in 
syngeneic transplantation. As mentioned before, even though allogeneic transplantation is 
done between HLA identical donor and recipient, differences between minor 
histocompatibility system (mHA) induce GVHD. These differences are bigger if a donor is 
unrelated, which explains higher incidence of GVHD in patients treated with unrelated when 
compared to sibling allogeneic transplantation. 
A modern perspective of GVHD pathophysiology can be summarized into a «three-step 
model»
34
: In step I, the conditioning regimen (high dose irradiation, chemotherapy, or both) 
leads to the damage of host tissues, especially the intestinal mucosa. This allows the 
translocation of lipopolysacharide (LPS) from the intestinal lumen to the circulation, 
stimulating the secretion of the inflammatory cytokines from host tissues (such as TNF alpha, 
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IL1, IL6). These cytokines will increase the expression of MHC antigens on host tissues, 
enhancing the recognition of these antigens and minor histocompatibility antigens (mHAs) by 
mature donor T cells. In step II, antigen-presenting cells (APC) present host antigens to donor 
T-lymphocytes and activate the immune response. This is characterized by the predominance 
of T-helper 1 (Th1) cells and the secretion of IFN gamma, as well as other cytokines. In step 
III, effector functions of immune cells are triggered by the secondary signal provided by LPS 
and other stimulatory molecules that leak through the intestinal mucosa damaged during steps 
I and II. Effector Th1 lymphocytes activate macrophages, along with cytotoxic lymphocytes 
(CTL), which secrete inflammatory cytokines that cause target cell apoptosis. CD8+ CTL also 
lyse target cells directly. Damage to the gastro-intestinal tract in this phase, principally by 
inflammatory cytokines, amplifies LPS release and leads to the so-called ‘‘cytokine storm’’, 
characteristic of severe GVHD. 
1.1.4. Novel strategies in allogeneic transplantation due to graft-versus-leukemia effect 
(GVL) - donor lymphocyte infusion (DLI) and non-myeloablative conditioning 
The graft-versus-leukemia effect of transplanted hematopoietic cells
9,10
 was first reported in 
early mouse studies. It was suggested that a reaction of the donor bone marrow against the 
host leukemia might kill cancer cells, and this was termed ‘adoptive immunotherapy’. 
However, the value of GVL effect was not fully recognized untill early 1980-s, when a group 
from Seattle published two systematic analysis of their previous transplantations and reported 
that recipients of hematopoietic stem-cell transplantations who developed GVHD were less 
likely to suffer cancer relapse.
35,36
 The importance of T cells in securing long-term 
engraftment and launching an attack on tumor cells was confirmed in 1990-s in a 
retrospective analysis of data from International Bone Marrow Transplant Registry (IBMTR). 
In this study, patients who received T-cell-depleted grafts experienced less GVHD, but also 
experienced increased graft failure and profoundly higher relapse rates (Figure 1).
37 
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Figure 1. The probability of relapse after allogeneic transplantation in patients with 
leukemia in relation to type of transplant and GVHD. 
 
Further support for this postulate came from adoptive immunotherapeutic attempts to induce 
GVHD and antitumor effects through the infusion of donor lymphocytes. In 1990-s, Hans-
Jochem Kolb was the first to successfully treat three chronic myeloid leukemia (CML) 
patients with a combination of interpheron alpha and infusion of „buffy coat“  (separated 
leukocytes and thrombocytes) from peripheral blood of donors.
38  
Infused donor lymphocytes become sensitized to surface antigens that are expressed on the 
leukemic cells, either to polymorphic minor histocompatibility antigens or leukemia-
associated antigens, and are transformed into cytotoxic lymphocytes that kill the leukemic 
cells. The most astonishing graft-versus-tumor effects after donor lymphocyte infusions (DLI) 
have been observed in patients with CML.
39,40
 Approximately 75% of relapsed chronic 
leukemia patients experience remission after DLI, whereas results are less impressive in 
patients with acute leukemias and multiple myeloma. It is presumed that in CML part of the 
malignant clone are host antigen-presenting cells (dendritic cells), which activate infused T-
lymphocytes.
41 
In some patients, graft-versus-tumor effects are associated with GVHD, whereas in others 
remissions are achieved without GVHD. The tumor responses seen in the latter patients are 
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probably due to expression of the polymorphic minor histocompatibility antigens only on the 
tumor cell surface and not on all hematopoietic cells, which serve as targets for the immune 
attack.
14,42-44 
All this described findings have changed the old paradigms for hematopoietic stem cell 
transplantation. Because of its risks, the conventional myeloablative stem cell transplantation 
was restricted to relatively young patients who are in good medical condition. As a result, 
very few patients older than 50 years and virtually none older than 60 years have been treated 
by conventional allogeneic transplantation. The age restriction is unfortunate, because the 
median ages at diagnosis of patients with most candidate diseases for allogeneic 
transplantation range from 65 to 70 years. However, investigators have recently developed 
less intensive hematopoietic stem cell transplantation programmes, also known as non-
myeloablative or mini-transplant approaches. These approaches require lower levels of 
chemotherapy and irradiation and rely on the graft-versus-tumor effects of the bone marrow 
transplantation, rather than the myeloablative effects of irradiation and chemotherapy to kill 
cancer cells.
45-51
 These regimens have been, in part, directly translated from preclinical 
models.
52,53
 In this type of transplantation, patients receive non-myeloablative irradiation or 
chemotherapy, immunosuppressive drugs and hematopoietic stem cell transplantation. After 
receiving the transplant, the recipient typically experiences mixed chimerism, in which the 
blood system is made up of a combination of host and donor cells (determined by 
microsatellite analysis). If the patient does not experience GVHD, s/he might be infused with 
more donor lymphocytes, leading to a conversion of completely donor-derived hematopoietic 
cell populations. This leads to graft-versus-tumor effects and cure of the malignancy. 
1.2. Antigen-presenting cells (APC) 
APC are highly specialized cells which can process antigens and present their peptide 
fragments on the cell surface together with the co-stimulatory molecules necessary for T-cell 
activation.
13
 Dendritic cells (DC) are key antigen-presenting cells that originate from bone 
marrow precursors and play a strong and central role in innate and adaptive immunity to 
infections and antigens in vivo.
54,55
 DC circulate in the blood before migrating to peripheral 
lymphoid tissues or inflammation sites. In response to microbial stimuli or inflammatory 
cytokines DC go through differentiation and maturation by decreasing ability of uptaking new 
antigens, increasing the expression of MHC antigens and co-stimulatory molecules as well as 
adhesion molecules and chemokine receptors which helps them migrate to lymphoid tissues. 
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In lymph nodes DC take up and process antigens to prime T cell responses.
56-62
 Besides T 
cells, cytokine-activated or mature DC activate other innate immune cells such as natural 
killer cells, natural killer T cells and B cells
63,64 
and polarize the immune response to either 
Th1 or Th2 types. 
65
 In addition, DC can induce antigen-specific unresponsiveness or even 
tolerance. In the absence of an activating signal, immature DC process antigens and present 
them to T-lymphocytes without co-stimulatory molecules which induces anergy and deletion 
of T-cells. There is increasing evidence that in some clinical situations including 
autoimmunity and certain infectious diseases DC induce immune tolerance either by deleting 
self-reactive T cells or by regulating or suppressing other immune T cells with T-regulatory 
lymphocytes (Tregs).
66
 
DC mature in response to two different signals- by recognizing the pathogen directly through 
pattern-recognition receptors or indirectly by recognizing the signs of infections as 
inflammatory cytokines. The most important surface receptors which can induce the 
maturation of DC are Toll-like receptors (TLR) following exposure to pathogen-associated 
molecular patterns (PAMPs). DC mature in response to different PAMPs, recognized by 
different TLR. For example, TLR4 recognizes LPS, TLR2 recognizes bacterial 
peptidoglicozides as part of bacterial wall in gram positive bacteria, TLR5 recognizes 
bacterial flageline, TLR9 recognizes CpG and TLR7 recognizes imidazoquinolones.
67 
Human blood precursor DC numbers are low, namely in the order of 0.1 – 0.7% of 
mononuclear cells
68-71
 and peripheral blood contains at least 2 major DC subsets with distinct 
phenotypes and distinct allostimulatory capacity. 
Myeloid DC (mDC) originate from bone marrow precursors, differentiate along the 
monocyte/macrophage lineage and require the presence of granulocyte-macrophage colony-
stimulating factor (GMCSF) for survival. Mature mDC produce high levels of interleukin12 
and other Th1-polarising signals.
65
 
Lymphoid or plasmacytoid DC (or pDC) depend on interleukin 3 for their survival and after 
activation secrete type I IFN, activate mDC, but can also polarize T-cell differentiation into 
Th2 cells.
65
 
1.2.1. Plasmacytoid dendritic cells 
Plasmacytoid dendritic cells also known as the type I IFN-producing cells, are a major 
member of the innate immunity effectors in both humans and mice. pDC display plasma cell 
morphology, selectively express TLR7 and TLR9, and are specialized in rapidly secreting 
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massive amounts of type I IFN following viral stimulation. Activated pDC can promote the 
function of NK cells, B cells, T cells, and mDC through type 1 IFN during an antiviral 
immune response but inactivated pDC can also induce antigen- specific anergy.
72 
pDC accumulation in lymphoid tissues, mucosa and organs occurs during many viral 
infections (HSV
73
, VZV
74
, HCV
75, 
influenza
76-78
, RSV
79,80
) and several human pathologies, 
particularly in lymph nodes of patients affected by sarcoidosis, Mycobacterium tuberculosis 
infection
81 , Kikuchi’s disease82 and in the skin of patients affected by psoriasis83,84, systemic 
lupus erythematosus (SLE)
85
,
 
and lichen planus
86,87
. pDC accumulation
 
has also been 
observed in brain
 
lesions of patients with multiple sclerosis
88
, in the salivary glands of patients 
with
 
Sjogren’s syndrome89 and the synovia or inflamed muscle tissue/skin of people afflicted 
with rheumatoid arthritis
90,91
or dermatomyositis
92,93
, respectively. 
The accumulation of pDC in several viral models and disease settings has been well defined, 
but the role of pDC in the pathogenesis and progression of diseases stays controversial, as 
their both negative and positive effects have been demonstrated. 
According to several studies, pDC are considered to be the culprits in promoting SLE and 
psoriasis,
94-99
 where they produce IFN-I in response to self-DNA.
100
 Blocking IFN-I strongly 
inhibits the T-cell-dependent progression of psoriasis, thus implicating pDC as critical 
mediators of disease.
84
 
On the other side, although activated pDC appear to behave as immunogenic cells, 
unstimulated or alternatively stimulated pDC can alleviate protective immunogenic responses 
through the induction of T-regulatory lymphocytes (Tregs). pDC induce Tregs via several 
mechanisms, and this has been particularly studied in breast cancer
101
 and melanoma
101,102
, as 
well as in HIV infection.
103,104 
1.2.2. pDC in GVHD 
After allogeneic stem cell transplantation, host DC are usually rapidly replaced by donor DC 
precursors except for Langerhans cells of the skin, which have been shown to be of host 
origin for at least 18 months.
105
 In murine allogeneic bone marrow transplantation as well as 
in humans it was shown that, despite the presence of numerous donor DC, only host-derived 
DC initiate acute GVHD, whereas development of chronic GVHD seems to require both 
donor and host DC, depending on the target organ involved.
106-109
 Donor DC can intensify 
GVHD probably by cross-priming alloreactive cytotoxic T-lymphocytes.
106,109-111
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In mice exposed to total body irradiation (TBI) host pDC can prime donor T-cells and cause 
GVHD, but this process does not require TLR signaling. It is assumed that an inflammatory 
environment created by host irradiation has the decisive role in maturing pDC for T-cell 
priming.
112
 In a similar model, infusion of immature pDC can effectively prevent GVHD by 
inducing Tregs.
113 
In human studies, delayed DC recovery and lower DC numbers, especially of pDC, are found 
in patients with acute and chronic GVHD and/or steroid treatment
114-116
, and a low pDC count 
in the peripheral blood on day +28 after transplantation was shown to be predictive for both 
acute and chronic GVHD.
117
 However, in other studies, high numbers of mDC and pDC have 
been observed during the early phase of acute GVHD, as well as chronic GVHD.
118-122
  
These studies show that the impact of DC accumulation on immune responses is still 
controversial and is probably dependent on their activation state, distribution and migration 
patterns. More studies are needed to elucidate this problem. Another important challenge in 
the field is to target pDC for therapeutic purposes. BDCA2 is a molecule expressed 
exclusively by human pDC, which provides an attractive target for the development of human 
pDC depleting antibodies.
123,124
 On the other hand, infusion of tolerogenic or activated pDC 
may be useful therapies for transplantation and cancer, respectively. 
1.3. CD4+ T helper (Th) lymphocytes 
CD4+ T helper (Th) lymphocytes are essential mediators of immune responses and 
inflammatory diseases. After being activated by professional APC, Th cells differentiate into 
effector cells specialized in cytokine secretion and function. In the past, effector Th cells have 
been classified as type 1 (Th1) and type 2 (Th2) based on their cytokine expression profiles 
and immune regulatory function.
125
 Th1 cells produce IFN gamma and mediate cellular 
immunity, whereas Th2 cells produce interleukin 4 (IL4), IL5 and IL13 and mediate humoral 
immunity and allergic responses. Th cell differentiation is regulated by the interaction of 
naive CD4+ T-cells with APC that express specific peptide MHC class II complexes, 
costimulatory molecules and inflammatory cytokines. Naive T-cell activation normally 
requires two signals: T cell receptor (TCR) signals, and costimulation through several 
accessory molecules. The main costimulatory molecule on Th cells is CD28
126
 which interacts 
with CD80 and CD86 expressed on mature DC. In addition to TCR and costimulatory 
molecules, IL12 produced by activated mDC is critical in Th1 differentiation.
127
 Additional 
cytokines in the IL12 family, IL23 and IL27, are also important for Th cell differentiation and 
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function.
128,129
 Other cytokines also influence the development of effector functions of Th 
cells; for example, IL4 produced by activated T cells (and perhaps by other innate cells as 
well) is crucial in driving Th2 differentiation.
130
 
Recently, a third subset of CD4+ effector cells has been identified; termed Th17, because the 
signature cytokine produced by this subset is IL17.
131-133 
Of note, T-regulatory lymphocytes (Tregs) are another subset of the immunosuppressive 
CD4+ T-cell lineage responsible for inducing immune tolerance.
134,135
 Thus, today we know 
that naive CD4 T cells can give rise to at least four distinct helper subsets of effector T cells at 
periphery (Th1, Th2, Th17 and Treg) depending on the presence of cytokines upon mitogenic 
stimulation. We now face a completely different and complex scenario, involving the new 
possible roles of Th17 cells and Tregs in immune responses and pathogenesis of diseases. 
1.3.1.Th17 subpopulation of lymphocytes 
Th17 cells are found in the systemic circulation and secondary lymphoid organs and tissues, 
particularly in the intestinal mucosa where they protect the host from microorganisms that 
invade through the epithelium.
136 
Th17 cells are characterized by their expression of 
proinflammatory cytokines IL17, IL21, and IL22, cytokines involved in neutrophilia, 
production of antimicrobial peptides and tissue repair.
137-140
  
IL17 is also produced by innate immune cells in an inflammatory milieu, and may have a 
central role in the initiation of IL17-dependent immune responses even before Th17 
development.
141
 Th17 cells differentiate from naive CD4+ T cells by stimulation with 
antigens in the presence of TGF beta and IL6 or IL21 both in mice and humans. Recent 
studies have shown that pDC can drive the differentiation of IL17 and IL22 producing T cells 
and that IL6 is implicated in this process.
142-144
 
IL17 belongs to a family of six members and among them, IL17A and IL17F are by far the 
best characterized.
145
 Many in vitro studies have indicated a proinflammatory function for 
IL17A which has been associated with many inflammatory diseases such as rheumatoid 
arthritis, asthma, SLE and psoriasis, respectively.
146-149
 CD161+Th17 population has been 
demonstrated  to have a proinflammatory role in Crohn's disease.
150 
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1.3.2. Th subsets in GVHD 
Until recently, CD4+Th1 cells were held responsible for the development of acute GVHD and 
CD4+Th2 for the development of chronic GVHD.
151
 The role of Th17 responses in GVHD 
has not yet been established and research on Th17 in GVHD is rapidly developing.  
Controversy exists in both mice and humans regarding the role of Th17 cells in the 
pathogenesis of GVHD. In murine model, some studies showed a protective role of IL17. In 
these studies infusion of IL17-deficient donor T cells induced more severe GVHD than that of 
wild-type T cells, and this was in association with enhanced Th1 differentiation of donor T 
cells by increased production of IL12 from DC in the absence of IL17.
152 
By contrast, other 
studies indicated a pathogenic role of IL17 in GVHD.
153,154
 Of note, infusion of Th17 cells 
caused lethal GVHD hallmarked by extensive tissue damage in irradiated mice.
155 
Further 
studies in mice showed that liver and gut GVHD is largely Th1 dependent, whereas skin 
GVHD is more Th17 dependent and lung GVHD is Th2 dependent.
156
 
Clinical studies assessing the correlation between Th17 cells with GVHD have also shown 
conflicting results. Th17 cells are increased in peripheral blood of patients with acute GVHD 
in one study
157
, but not another study.
158 
Ratio of Th17 to Treg was found to be increased in 
the biopsied samples of GVHD tissues in one study
157
, whereas it was decreased in another 
study.
159
 It was also shown that Th17 cells were not increased in the skin in contrast to a 
significant increase in Th1 IFN gamma producing cells at the onset of acute GVHD.
158
 
Schematically, it is likely that all four populations of T-helper cells: Th1, Th2, Th17, and 
Tregs pathways cross-regulate in the immune system. In allogeneic transplantation depending 
on the initiating signal delivered to DC during or after the conditioning regimen, the IL12/IFN 
gamma, IL23/IL17 or Tregs axes may become a more or less prominent pathway, and the 
dominance of one axis to another may lead or not to breakdown of tissue-specific immune 
tolerance. A key question is why the regulatory mechanisms fail to shut down the stimulatory 
pathways in GVHD. 
In order to modulate the balance of Th subsets in vivo, the use of biological products such as 
cytokine-neutralizing monoclonal antibodies has increasingly been used clinically in treating 
patients with cancer and autoimmune diseases, and it represents a realistic and attractive 
strategy because cytokine environment is critically important for T helper and Treg 
differentiation. To establish highly effective Treg therapy or cytokine modulation, 
consideration of timing of administration is particularly important in the setting of highly 
inflammatory allogeneic stem cell transplantation. However, as reduced intensity conditioning 
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(RIC) has been developed to minimize toxicity of conditioning regimen, advances in 
transplant medicine will synergistically facilitate development of such novel strategies. 
Conversely, results from animal studies suggest that a combined blockade of Th1 and Th17 
differentiation pathways of donor T cells may represent a promising strategy for the 
prevention or treatment of GVHD, while inhibition of either pathway alone seems to be 
insufficient to prevent GVHD.152,160,161 
1.4. Pro-inflammatory cytokines and chemokines  
Cytokines are a group of small peptides or glycoproteins produced by a wide variety of 
immune and inflammatory cells with molecular weights between 8 and 30 kDa. They had 
been shown to play an essential role in cell comunication and modulation of the immune 
response.
162
 The „cytokine storm“ has already been defined in the pathophisiology of 
potentially fatal immune reactions. This reaction consists of a positive feed-back loop 
between cytokines and immune cells and can also lead to severe GVHD. Chemokines are a 
large family of very small 8 to 12 kDa cytokines that have been discovered more recently and 
which primarily function as leukocyte chemoattractants.
163,164
 It has been demonstrated that 
members of the chemokine superfamily are involved in immunological and 
autoimmunological diseases.
165-167
 
These mediators have been classified according to several classifications. The classical 
classification separates cytokines into five groups; interleukins mostly produced by T-
lymphocytes (IL1 to IL35), interferons (IFN types I-III), cytotoxins produced by macrophages 
and cytotoxic lymphocytes which cause target cell death (TNF alpha and TNF beta), colony-
stimulating factors (CSF) and finally other cytokines which can not be otherwise classified (as 
TGF beta, leukemia inhibitory factor (LIF) or macrophage migration inhibitory factor (MIF). 
The second classification also separates cytokines into five groups according to the structure 
and mechanism of action of their receptors; type I cytokine receptor family (hematopoietin 
receptors), type II cytokine receptor family (interferon receptor family), TNF-receptor family, 
immunoglobulin receptor family and chemokine receptor family. Finally, the third 
classification divides the cytokines into four groups according to their function- innate 
immunity (pro-inflammatory) cytokines, specific (adoptive) immunity cytokines, 
immunosupressive (immunoregulatory) cytokines and colony stimulating factors. These 
cytokines and their cross reactive functions are presented in Figure 2. 
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Figure 2. The functional classification of cytokines 
CSF indicates colony stimulating factor (G, granulocyte; M, macrophage; GM, granulocyte-
macrophage.), IL interleukin; IFN, interferon; MIP, macrophage inflammatory protein; TGF, 
transforming growth factor; TNF, tumor necrosis factor;  
 
The family of chemokines is sub-divided according to the number and position of NH2- 
terminal cysteine (C) residues. The majority of chemokines fall into the CC (CCL1-28) and 
CXC (CXCL1-16) subfamilies, while the C family contains only 2 members (XCL1 and 
XCL2) and CX3C only 1 member (CX3CL1). There is significant redundancy in the 
chemokine system as shown in Figure 3. by the binding of multiple chemokines to a 
particular receptor and multiple receptors interacting with a particular chemokine. There are 
currently 10 identified CC chemokine receptors (CCR1-10), 6 CXC receptors (CXCR1-6), 1 
C receptor (XCR1), and 1 CX3C receptor (CX3CR1).
168,169
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Figure 3. Inflammatory chemokines and receptors 
APC indicates antigen-presenting cell; B, B cell; D, dendritic cell; E, eosinophil; L, 
Langerhans cell; Ma, mast cell; M_,macrophage; N, neutrophil; NK, natural killer cell; P, 
platelet; T1, TH1/TC1 cell; and T2, TH2/TC2 cell. DC indicates dendritic cell; GRO, growth-
related oncogene; I-TAC, inducible T cell alpha chemoattractant; MCP, macrophage 
chemotactic protein; HCC, hemofiltrate CC chemokine; MIP, macrophage inflammatory 
protein; RANTES, regulated on activation normal T cell expressed and secreted; TARC, 
thymus and activation regulated chemokine; MDC, macrophage-derived chemokine; CTACK, 
cutaneous T-cell–attracting chemokine; MEC, mucosae-associated epithelial chemokine; and 
TECK, thymus-expressed chemokine. 
 
1.4.1. Cytokines and chemokines in GVHD 
The role of proinflammatory cytokines such as TNF alpha and IL1, has been extensively 
studied in murine and human studies in the context of acute GVHD.
170
 The role for TNF alpha 
in clinical acute GVHD has been suggested by studies demonstrating elevated levels of TNF 
alpha in the serum of patients with acute GVHD as well as the studies in which target organ 
damage could be inhibited by infusion of anti-TNF alpha monoclonal antibodies.
171,172
 
The other well-studied proinflammatory cytokine that plays a role in acute GVHD is IL1. 
Secretion of IL1 appears to occur predominantly during the effector phase of GVHD of the 
spleen and skin and mice receiving IL1 after allogeneic stem cell transplantation display an 
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accelerated form of GVHD.
173,174 
Although administration of an IL1 receptor antagonist to 
recipients reduces GVHD mortality in animal models
175
, human studies failed to demonstrate 
any significant benefit against acute GVHD.
176 
Among all other cytokines that have been extensively studied in GVHD, several cytokines 
emerged as significantly correlated with development and severity of GVHD. In one study, 
IL12p70, a cytokine mainly produced by mDC, was significantly associated with clinically 
severe GVHD development, probably through activation of Th1 subpopulation of T-
lymphocytes.
177
 In another study, a higher production of another cytokine, IL10  (produced by 
DC and Th2 cells) was associated with reduced incidence and severity of acute GVHD.
178,179
 
Paradoxically, high-serum IL10 levels in patients after allogeneic transplantation were 
associated with a fatal outcome
180
, whereas administration of low doses of IL10 was found to 
be protective in murine acute GVHD.
181 
Recently, the role of chemokines and integrins in the migration of donor T cells to tissue sites 
of GVHD has been examined in mice following allogeneic stem cell transplantation.
182
 Gene 
expression profiling of GVHD target organs has identified elevated expression of the 
proinflammatory chemokines CCL2/MCP1, CCL3/MIP1a, CCL4/MIP1b, CCL5/RANTES, 
CXCL9/MIG, and CXCL10/IP10.
183-185 
 
All these findings show that dose and timing of cytokine production are critical factors in the 
induction and development of GVHD. More studies have to be done in order to investigate 
other potentially important cytokines and their roles in the „cytokine storm“ dogma as they 
represent attractive  diagnostic tool and an attractive therapeutic targets as well.
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2. Hypotheses 
1. The number and function of circulating pDC and Th17 cells is correlated with 
development and severity of GVHD. 
2. The number and function of circulating pDC and Th17 cells is correlated with the 
outcome of patients. 
3. A valuable predictive and prognostic score for the development of GVHD can be 
made by the use of significant serum cytokines. 
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3. Aim and purpose of the research 
The main aim of this research was to quantify plasmacytoid dendritic cells and Th subsets 
(Th1 and Th17 subpopulations) in peripheral blood of patients at day 100 after allogeneic 
stem cell transplantation. 
Specific aims of this research were: 
1. To quantify specific intracellular cytokines in plasmacytoid dendritic cells and Th 
subsets at day 100 after allogeneic stem cell transplantation. 
2. To quantify specific serum cytokines at day 100 after allogeneic stem cell 
transplantation. 
3. To evaluate correlation of plasmacytoid dendritic cells and T helper subsets with the 
development of GVHD and its severity. 
4. To evaluate the specific correlation of plasmacytoid dendritic cells and T helper 
subsets with development of relapse and outcome of patients. 
5. To make a prognostic score for the development of GVHD based on the significant 
cytokines. 
 
The purpose of this research was to allow better understanding of the pathophysiology of  
GVHD and GVL. In addition to its cognitive value, this might also identify specific molecules 
important for development of GVHD and GVL. These molecules could then not only be used 
as diagnostic markers, possibly enabling earlier treatment of GVHD, but would also offer the 
attractive possibility of their specific targeting in vivo. This could maybe pave the way for 
novel, more specific and less toxic therapeutic interventions in this field. 
4. Material, subjects, methodology and research plan  
The research was done in the University Hospital Centre in Nantes, France, (CHU de Nantes) 
under the mentorship of professor Mohamad Mohty and as a part of his project «Facteurs 
prédictifs de la reaction du greffon contre l’hôte après alogreffe de cellules souches 
hématopoietiques» («Predictive factors for graft versus host reaction after allogeneic stem cell 
transplantation»). The research was done in collaboration with Hematology Division of 
Department of Internal Medicine of School of Medicine, University of Zagreb, within a 
project „Leukemias and hematopoietic stem cell transplantation“ and under the mentorship of 
professor Boris Labar. 
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4.1. Subjects 
This research included 79 patients treated with allogeneic stem cell transplantation at 
University Hospital Centre in Nantes. Serum cytokines were additionaly evaluated in 73 more 
patients treated with allogeneic stem cell transplantation at the same institution (152 patients 
in total). 
4.2. Material 
Biological material (blood samples) was obtained after informed consent of the patients, and 
as part of the material usually collected for routine care of the patients after allogeneic stem 
cell transplantation in CHU de Nantes. For the purpose of this project, such “biocollection” 
has been declared and approved by the French Ministry of Health and regulatory authorities 
(Reunion de concertation pluridisciplinaire in CHU de Nantes), which is a local authority for 
ethical aspects of this kind of research.  
4.2.1. Blood samples 
All blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes and 
peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation. 
All the cells, as well as serums, were then cryopreserved in 0.5-mL aliquots at -80°C. 
4.3. Methodology and research plan 
4.3.1. Treatment with reduced-intensity conditioning allogeneic stem cell transplantation 
The majority of the patients were treated with reduced-intensity conditioning (RIC) allogeneic 
stem cell transplantation. The RIC regimen was mainly based on fludarabine in a dose 30 
mg/m
2 
daily over 4-6 days, IV busulfan 3.2 mg/kg daily over 2-3 days, and anti–thymocyte 
globulin (ATG) (Thymoglobuline; Genzyme, Lyon, France) for a total dose of 5 mg/kg 
infused over 2 days.
186 
All donor/recipient pairs were typed at the allelic level, according to the recommendations of 
the European Federation for Immunogenetics (EFI) Histocompatibility Laboratory standards. 
A single HLA mismatch of 10 (at HLA-C) was allowed at the allele level. Grafts were 
obtained from HLA-identical sibling donors or from HLA-matched or mis-matched unrelated 
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donors. Patients usually received peripheral blood stem cell allografts, mobilized from donors 
with granulocyte-colony-stimulating factor (GCSF) (10 μg/kg per day). 
4.3.2. Prophylaxis, diagnostics and treatment of GVHD 
GVHD prophylaxis was performed with cyclosporin A (CSA) alone after related allogeneic 
stem cell transplantation or with CSA and mycophenolate mofetil (MMF) after unrelated 
allogeneic stem cell transplantation. In the absence of GVHD, MMF and CSA were tapered 
over 4 weeks starting from day 60 and day 90, respectively.
187
 Acute GVHD was evaluated 
according to standard Seattle criteria.
188
 On diagnosis of grades II to IV acute GVHD, all 
patients were primarily treated with CSA and methylprednisolone in a dose of 2 mg/kg per 
day. Acute GVHD and chronic GVHD were arbitrarily separated by day 100 after allogeneic 
stem cell transplantation. Chronic GVHD was clinically evaluated as limited or extensive. On 
diagnosis of extensive GVHD, all patients were primarily treated with methylprednisolone (1 
mg/kg per day).
189 
4.3.3. Collection of blood samples 
All blood samples were collected and then cryopreserved at day 100 after allogeneic stem cell 
transplantation. 
4.3.4. Flow cytometry analysis and intracellular cytokine staining 
4.3.4.1. Plasmacytoid dendritic cells 
Cryopreserved cells were thawed and stimulated for 6 hours with TLR7 ligands (R848, in a 
concentration 5 µg/ml) and TLR9 (CpGA, in a concentration 10 µg/ml), in the presence of 10 
ng/ml IL3. Two hours after the beginning of stimulation, 10 µg/mL Brefeldin A was added to 
stop the extracellular secretion of intracellular cytokines. 
For surface markers, cells were then stained according to manufacturer’s protocol with 
conjugated antibodies Pacific Blue HLA-DR (from Biolegend), Pe-Cy7 CD123 (from 
Biolegend) and APC BDCA2 (from Miltenyi). Cells were then fixed and permeabilized using 
Cytofix/Cytoperm reagents (BD Biosciences) and then incubated with PE IFN alpha (from 
Miltenyi), FITC IL6 (from Biolegend) and PerCp-Cy5.5 TNF alpha (from Biolegend). 
Finally, cells were analyzed on a FACSCanto II using DIVA software (BD Biosciences). 
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4.3.4.2. Subpopulations of T-helper cells 
The same PBMC were stained for cell-surface markers according to standard protocols with 
conjugated antibodies V500 CD3, APC CD8 (both from BD Biosciences), Pe-Cy7 CD4, PE 
CCR10, PerCp-Cy5.5 CD161 Pacific Blue CXCR3 (all from Biolegend) and FITC CCR6 
(from R&D Systems). 
For analysis of intracellular cytokine production, PBMC were stimulated with phorbol 
myristate acetate (PMA) (25ng/ml) and Ca2+ ionophore (1µg/ml) for 4.5 hours, with 
Brefeldin A (10μg/ml) added for the final 3.5 hours. For surface markers, cells were stained 
with conjugated antibodies V500 CD3, FITC CD8 (both from BD Biosciences) and Pe-Cy7 
CD 4 (from Biolegend). Cells were then fixed and permeabilized by using Cytofix/Cytoperm 
reagents (BD Biosciences) and then stained for intracellular cytokines with conjugated 
antibodies PE IFNgamma (from Diaclone), PerCp-Cy5.5 TNFalpha (from Biolegend), V450 
IL17A and AF647 IL21 (both from BD Biosciences) according to the manufacturer’s 
protocols. Finally, cells were analyzed on a FACSCanto II using DIVA software (BD 
Biosciences).  
4.3.5. Cytokine analysis in peripheral blood 
Forty one different cytokines, chemokines, colony stimulating factors, cytotoxins and 
interferons (IL1a, IL1b, IL1ra, IL2, IL2ra, IL4, IL5, IL6, IL7, IL9, IL10, IL12p40, IL12p70, 
IL13, IL15, IL17, IL21, IL23, IL8 (CXCL8), IP10 (CXCL10), MCP1 (CCL2), MIP1a 
(CCL3), MIP1b (CCL4), RANTES (CCL5), MCP3 (CCL7), TARC (CCL17), MDC 
(CCL22), FRACTALKINE (CX3CR1), IL3 (multi-CSF), VEGF, PDGFABBB, TNF alpha, 
TNF beta, TRAIL, CD40L, BAFF, IFN a2, IFN gamma,  ELAFIN, TGF alpha, FLT.3L) were 
quantified from the collected serums using a commercially available Luminex-xMAP system. 
Luminex is a system of an immune test with xMAP microspheres which are then analyzed in 
the Luminex analyzer. Antibodies to cytokines are coated to microspheres which are 
internally dyed with different intensities of two fluorophores allowing detection of a large 
number of cytokines from the same sample at the same time. As the microsphere passes 
through the cytometer the red laser excites the fluorophores while the green laser excites the 
reporter molecule also coated to a microsphere and makes it possible to quantify the reaction. 
Finally the results were analyzed with xPONENT software. 
  
22 
 
 
4.3.6. Statistics 
The data were computed using the R package (R Development Core Team, 2006. R: A 
language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.)  
The Mann–Whitney test was used for comparison of continuous variables. Categorical 
variables were compared using the chi square or Fisher's exact test. The probability of 
developing acute and chronic GVHD was depicted by calculating the cumulative incidence 
treating death as a competitive risk.
190
 Cumulative incidence estimates were also used to 
measure the probability of relapse. Probabilities of overall survival (OS) were estimated from 
the time of transplantation using the Kaplan–Meier product-limit estimates.191 Differences 
between groups were tested using the logrank test. A multiple logistic regression with 
backward stepwise model selection was used to depict predictive factors for cell recovery at 
100 days after allogeneic stem cell transplantation. The association of time to death with the 
cell counts and other relevant variables was evaluated in a multivariate analysis with the use 
of Cox’s proportional-hazard regression model. 
The association of time to GVHD with cell counts and cytokine levels was evaluated first in 
the univariate analysis (with CI method). The association of development of chronic GVHD 
with cell counts and other relevant variables was evaluated in a multivariate regression 
analysis, using the semiparametric proportional hazards model of Fine and Gray.
192 
The threshold value of the each serum cytokine value was evaluated with the Hothorn and 
Zeileis recursive partitioning method, which is available as ctree function in the R package.
193
 
The association of time to GVHD with cytokine levels independent of the identified risk 
factors (factors with p value <0.20 in the univariate analysis) was evaluated in a multivariate 
analysis with the use of Grambsch and Therneau residual functional test for the Cox 
proportional hazards model.
194 
For making the prognostic score for development of GVHD at two years after allogeneic stem 
cell transplantation, we included both clinical variables and levels of cytokines which had a p-
value < 0.20 in the univariate analysis. The score was made as a sum of covariables multiplied 
with logarithms of the relative risks obtained in the Cox multivariate analysis. The sensitivity 
and specificity of the prognostic score was evaluated with the Heagerty method, the Kaplan-
Meier based time-dependent receiver operating characteristic (ROC)-curves.
195
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In order to avoid the “overfitting” of our prognostic score (related to the great number of the 
variables that will be included), and to get a reliable estimate, we used additional techniques, 
as 0.632 bootstrap resampling method for repeated cross-validation.
196
 
5. Results 
5.1. Study population characteristics 
Patients' characteristics are summarized in Table 1. Briefly, the first part of the study included 
42 male patients (53%) and 37 female patients (47%) that received allogeneic stem cell 
transplantation between years 2009 and 2011. The median age of recipients was 54 (range 25-
71) years. In all, 37 patients were treated with allogeneic stem cell transplantation for acute 
leukemias (45%), 14 patients (18%) were treated for myelodysplastic and myeloprolipherative 
syndromes, 14 patients (18%) for lymphomas, 5 patients (7%) were treated for chronic 
leukemia, 7 patients (9%) for multiple myeloma and finally, 2 patients (3%) for aplastic 
anemia. Patients with acute leukemia in first complete remission, patients with chronic 
myeloid leukemia in chronic phase and patients with untreated disease were considered as 
standard risk patients while all other patients were considered as high risk patients. In total, 
there were 70 high risk patients (89%) and 9 standard risk patients (11%). Allogeneic stem 
cell transplantation was done after a myeloablative conditioning in 9 patients (11%) and after 
a reduced-intensity conditioning in 70 patients (89%). GVHD prophylaxis was done with 
cyclosporine A alone in 30 cases (38%), with a combination of cyclosporine A and 
mycophenolate mophetil in 40 cases (51%) and with cyclosporine A and methotrexate in 9 
cases (11%). Donors were male in 49 patients (62%) and female in 30 patients (38%). In 36 
patients (45%) donors were identical siblings, in 29 patients (37%) matched unrelated and in 
14 patients (18%) mismatched unrelated. Twenty-three recipient-donor pairs were 
seronegative for CMV (29%). Stem cell source was peripheral blood in 55 patients (70%), 
bone marrow in 10 patients (12%) and cord blood in 14 patients (18%). Median count of stem 
cells infused at day 0 was 5.25x10
6
/kg body weight of recipient. 
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5.2. Transplant-related events and outcome after day 100 after allogeneic stem cell 
transplantation 
Transplant related events and outcomes are summarized in Table 2. Overall survival in our 
patients was 74% at two years, with a median follow up of 592 days for living patients. 
(Figure 4.) 
53 patients (67%) had no or had grade I acute GVHD and clinically significant grade II to IV 
acute GVHD (moderate to severe GVHD) occurred in 26 of cases (33%) at a median of 30 
days after allogeneic stem cell transplantation (with a range 8-91 days). The cumulative 
incidence of acute GVHD was 50% (95%CI, 38-61) at 20 months with cumulative incidence 
of significant acute GVHD (grades II-IV) of 36% (95%CI, 25-47) at 20 months. (Figures 5. 
and 6.) Two patients died from severe (grade IV) form of acute GVHD before day 100. 
Chronic GVHD was diagnosed in 49 of cases (62%), with limited form of chronic GVHD 
diagnosed in 25 of these patients (32%) extensive chronic GVHD occurring in 24 patients 
(30%). The cumulative incidence of chronic GVHD was of 66% (95%CI, 53-76) at 20 months 
with cumulative incidence of extensive chronic GVHD of 37 % (95%CI, 25-49) at 20 months. 
(Figures 7. and 8.) Chronic GVHD was diagnosed at a median of 134 days after allogeneic 
stem cell transplantation (with a range of 90-570 days). 
Median blood cell counts together with the immune status (CD4+ and CD8+ lymphocytes) 
and CMV antigenemia at day 100 after allogeneic stem cell transplantation are depicted in 
Table 1. 
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Table 1. Baseline demographic characteristics of study population 
 
Characteristic                                                                                             n (%) 
                                                                                                                                
Patient age, median (range)                                                                        54 (25-71) 
                                                   
Patient gender 
      Male                                                                                                           42 (53)          
      Female                                                                                                       37 (47) 
                                                                                      
Diagnosis
a
 
      Myeloid malignancy                                                                                  44 (56) 
         
Lymphoid malignancy                                                                               33 (42) 
      Aplastic anaemia                                                                                         2 (2) 
      
Disease risk
b
 
      Standard risk                                                                                               9 (11) 
      High risk                                                                                                    70 (89) 
 
Conditioning regimen 
      Myeloablative                                                                                             9 (11)     
      Reduced-intensity conditioning                                                    70 (89) 
 
GVHD prophylaxis 
      CsA alone                                                                                                  30 (38) 
      CsA and MMF                                                                                           40 (51)                                   
      CsA and MTX                                                                                            9  (11)     
 
Donor gender 
      Male                                                                                                           49 (62) 
      Female                                                                                                       30 (38) 
 
CMV serologic status, seronegative pair 
      Yes                                                                                                             23 (29) 
      No                                                                                                              56 (71) 
 
Donor type 
      Matched related donor                                             36 (45)          
      Matched unrelated donor                                                                           29 (37)                                    
      Mismatched unrelated donor                                                                     14 (18)                                         
 
Stem cell source 
      Bone marrow                                                                                             10 (12)                                                                                                     
      Peripheral blood                                                                                        55 (70) 
      Cord blood                                                                                                 14 (18)      
          
Cells infused (x10
6
/kg), median (range)                                                 5.25(0.06-10.1)                                                     
a
Myeloid malignancies included 28 acute myeloid leukemias, 10 myelodysplastic syndromes, 4 
myeloprolipherative syndromes and 2 chronic myeloid leukemias. Lymphoid malignancies included 12 non-
Hodgkin’s lymphomas, 9 acute lymphoblastic leukemias, 7 multiple myelomas,  3 chronic lymphocytic 
leukemias and 2 Hodgkin’s lymphomas.                                                           
b
Standard risk disease – acute leukemia in first complete remission, chronic myeloid leukemia in chronic phase 
and untreated disease, all others-high risk. 
CMV= cytomegalovirus, CsA=cyclosporine A, MMF=mycophenolate mofetil, MTX=methotrexate 
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Table 2.  Transplant-related events and outcome 
 
 
 
Characteristic                                                                                   n  (%) 
 
                                                                                                               
Neutrophil recovery                                                                                          
ANC > 0,5 x 10
9
 /L    
median (range)                                                                                               16 (8-43) 
                                                                                                                         
Acute GVHD
 
      grade 0-I                                                                                                      53 (67)                                                                                     
      grade II -IV                                                                                                 26 (33)       
 
Acute GVHD onset (days)                                                                              30 (8-91) 
after transplantation 
median (range) 
 
CMV antigenemia at 
 100 days after allo-SCT                           
       yes                                                                                                               36 (45) 
       no                                                                                                                43 (55)                                       
 
Blood cell counts at d+100                        
Leukocytes                                                                                               4.65 (1.0-16.4) 
Granulocytes                                                                                          2.57 (0.06-14.6) 
Lymphocytes                                                                                              0.94 (0.1-5.2) 
Monocytes                                                                                                  0.5 (0.02-1.6) 
CD4+                                                                                                  0.114 (0.001-0.98) 
CD8+                                                                                                      0.266 (0.02-2.7) 
       
Chronic GVHD 
       no or limited                                                                                               55 (70) 
       extensive                                                                                                     24 (30) 
 
Chronic GVHD onset (days)                                                                      134 (90-570) 
after transplantation 
median (range) 
 
Follow up days for surviving patients                                                        592(225-873) 
median (range) 
ANC=absolute neutrophil count, CMV=cytomegalovirus, GVHD=graft-versus-host disease 
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Figure 4. Overall survival in study population of 74% (95%CI 64-86%) at 22 months 
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Figure 5. Cumulative incidence of acute GVHD in study population of  50% (95%CI, 38-
61) at 20 months 
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Figure 6. Cumulative incidence of  II-IV acute GVHD in study population of  36% (95%CI, 
25-47) at 20 months 
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Figure 7. Cumulative incidence of chronic GVHD in study population of 66% (95%CI, 53-
76) at 20 months 
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Figure 8. Cumulative incidence of extensive chronic GVHD in study population of  37 % 
(95%CI, 25-49) at 20 months 
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5.3. pDC in peripheral blood of patients at day 100 after allogeneic stem cell 
transplantation 
5.3.1. Stimulation and analysis of pDC  
For functional characterization, thawed PBMC were stimulated with three different 
conditions: 
1. with IL3 
2. with IL3 + CpGA 
3. with IL3 + R848 
All three conditions included IL3, as this cytokine was shown to be necessary for the survival 
of pDC.
67 
The first condition included just IL3 and served as a negative controle. The other 
two conditions included ligands for specific TLR receptors present on pDC; CpGA, a ligand 
for TLR9 receptor and R848, a ligand for TLR7 receptor.
65 
Upon stimulation of TLR9, pDC 
secrete large amounts of cytokines- IFN alpha and TNF alpha, and upon stimulation of TLR7, 
pDC secrete large amounts of both IFN alpha and TNF alpha, together with IL6. 
As pDC are a rare population of cells and represent only of 0.1 – 0.7% of PBMC in the blood, 
a rather large number of cells needs to be stimulated to have some visible resultats on the flow 
cytometry at the end of the experiment. This is the reason why we used at least 10
6 
of thawed 
PBMC cells for each condition. For already known reasons, our population of patients is a 
population under immunosupressive treatment and a population with sometimes lower 
numbers of PBMC that could be cryopreserved. Actually, a median number of cryopreserved 
cells at day 100 for all our patients was 3.2 x 10
6
. It is known that, after thawing, a large 
number of cells is destroyed with DMSO and this is the reason why the number of cells at the 
beginning of stimulation was sometimes modest. It was planned to do all our experiments, 
both stimulation of pDC and lymphocytes, with the same PBMC from one sample per patient. 
All this led us to a conclusion that all conditions could not be done in all patients. Finally, the 
stimulation with CpGA (TLR9 ligand) was done in all 79 patients and the stimulation with 
R848 (TLR7 ligand) was done in 46 patients. (58% of cases). 
As described before, after 6 hours of stimulation, cell were stained for surface markers; HLA-
DR (a marker specific for dendritic cells), CD123 and BDCA2 (pDC express CD123high and 
BDCA2, which is expressed exclusively on human pDC). 
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After staining for cell surface markers, cells were fixed and permeabilized and finally stained 
for intracellular cytokines. As mentioned before, pDC were evaluated for production of 
following cytokines: IFN alpha (a signature cytokine for pDC), TNF alpha and IL6. 
Finally, pDC were evaluated by multicolor flow cytometry. The isotype controls in this 
experiment were not used because the condition with IL3 served as negative controle. We also 
used two healthy donors as positive controls. (an example of flow cytometry analysis of one 
of the patients with positive and negative controls is shown in Figures 9. -12.) 
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Figure 9. Stimulation with  IL-3 in a healthy donor (negative control); pDC were detected 
among mononuclear cells (A) as HLADR+ (B), CD123+ and BDCA2 (C) 
A 
B 
C 
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Figure 10. Stimulation with IL3 + CPG in a healthy donor (positive control); pDC were 
evaluated for production of IFN alpha (A, B), TNF alpha (A, C) and IL6 (B, C) 
 
C A B 
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Figure 11. Stimulation with IL3 + CPG in a patient from PBMC taken at day 100 after 
allogeneic stem cell transplantation 
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Figure 12. Stimulation with IL3 + R848 in a patient from PBMC taken at day 100 after 
allogeneic stem cell transplantation 
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5.3.2. pDC count and predictive factors for pDC recovery 
The median pDC count at day 100 after allogeneic stem cell transplantation in our group of 
patients was 0.2% of PBMC. We used this value to allocate the patients into a „low pDC“ 
recovery group (patients with pDC count <0.2% of PBMC) or „high pDC“ recovery group 
(patients with pDC count >=0.2% PBMC). Baseline demographic and transplant characteristic 
of these two groups were comparable and are shown in Table 3. Transplant-related events and 
outcome of the patients of the „low pDC“ and „high pDC“ recovery groups were also similar 
as it is shown in Table 4., except of the incidence of acute GVHD. Grade II-IV acute GVHD 
was observed in 19 patients (59%) in the „low pDC“ recovery group while grade II-IV acute 
GVHD occured only in 8 patients (17%) in the „high pDC“ recovery group.  
Therefore, we built a multivariate logistic regression model to explain pDC recovery in the 
blood of patients at day 100 after allogeneic stem cell transplantation. All variables with a p-
value < 0.20 in the univariate analysis were included in the model (diagnosis, gender of the 
donor, type of the donor, CMV antigenemia and acute GVHD). A backward stepwise 
selection was performed and we obtained a model with two variables- matched unrelated 
donor (OR = 0.84, 95% CI 0.68-1.03 p=0.09) and occurence of grade II-IV acute GVHD 
(OR= 0.67, 95% CI 0.54-0.83, p = 0.0004). Finally, only the absence of clinically significant 
grade II-IV acute GVHD was significantly associated with an impaired pDC recovery at day 
100 after allogeneic stem cell transplantation. 
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Table 3. Baseline demographic characteristics of “low”and “high” pDC group 
 
 
                                                                   “low pDC”                    “high pDC” 
Characteristi                                                               n (%)                              n (%)                      p-value 
                                                                                      n=32                                n=47                                  
Patient age, median (range)                                      54 (26-71)                       54 (27-69)                       0.65 
                                                   
Patient gender 
      Male                                                                      18 (55)                             24 (51)                         0.65                                                                                                            
      Female                                                                  14 (45)                             23 (49)                               
                                                                                      
Diagnosis
a
 
      Myeloid malignancy                                             18 (56)                             17 (36)                                                          
         
Lymphoid malignancy                                          13 (41)                             29 (62)                                                                       
      Aplastic anaemia                                                      1 (3)                                 1 (2)                         0.10 
      
Disease risk
b
 
      Standard risk                                                          13 (41)                            19 (40)                        
      High risk                                                                19 (59)                            28 (60)                        0.98                          
 
Conditioning regimen 
      Myeloablative                                                          3 (9)                               6 (13)                                       
      Reduced-intensity conditioning               29 (91)                             41 (87)                        0.64                                       
 
GVHD prophylaxis 
      CsA alone                                                                8 (25)                            18 (38)                         0.22                                              
      CsA and MMF /MTX                                           24 (75)                             29 (62)                                                                        
 
Donor gender 
      Male                                                                       17 (53)                            32 (68)                        0.18                                                                                   
      Female                                                                   15 (47)                            15 (32)                                                                             
 
CMV serologic status, seronegative pair 
      Yes                                                                           9 (28)                           14 (30)               
      No                                                                          23 (72)                           33 (70)                         0.87 
 
Donor type   
      Matched related donor                              10 (31)                            27 (57)                       
      Matched unrelated donor                                      12 (38)                            13 (28)                                                                              
      Mismatched unrelated donor                                 10 (31)                              7 (15)                        0.06                                                                          
 
Stem cell source 
      Bone marrow                                                          5 (16)                               5 (11)                                                                                                                                             
      Peripheral blood                                                    20(63)                             35 (74)                                                        
      Cord blood                                                              7 (21)                              7 (15)                         0.52                                    
         
Cells infused (x10
6
/kg), median (range)                6 (0.06-10.1)                 4.98 (0.07-10)                    0.17                    
                                                 
CMV= cytomegalovirus, CsA=cyclosporine A, MMF=mycophenolate mofetil, MTX=methotrexate 
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Table 4. Transplant related events and outcome of “low”and “high” pDC group 
 
 
Characteristic                                                         “ low pDC”                    “high pDC” 
                                                                                      n (%)                              n (%)                      p-value 
                                                                                      n=32                                n=47                                  
 
                                                                                                               
Neutrophil recovery                                                                                          
ANC > 0,5 x 10
9
 /L    
median (range)                                                         17 (11-32)                        16 (8-43)                       0.28              
                                                                                                                           
Acute GVHD
 
      grade 0-I                                                                13 (41)                           39 (83)                                                                                                      
      grade II -IV                                                           19 (59)                             8 (17)                     < 0.0001        
 
Acute GVHD onset (days)                                                                           
after transplantation 
median (range)                                                         29 (13-97)                      32 (8-91)                        0.56 
 
CMV antigenemia at 
 100 days after allo-SCT                           
       yes                                                                        24 (75)                           42 (89)                         0.09           
       no                                                                           8 (25)                             5 (11)                                                                 
 
Blood cell counts at d+100                        
Leukocytes                                                            4.9 (1.7-16.4)                 4.3 (1.0-13.1)                    0.18      
Granulocytes                                                         3.2 (0.8-14.6)                 2.4 (0.06-8.3)                     0.11                                             
Lymphocytes                                                          0.8 (0.1-5.2)                  1.0 (0.12-2.9)                    0.18                            
Monocytes                                                            0.4 (0.02-1.6)                 0.5 (0.02-1.5)                     0.64 
CD4+                                                              0.09 (0.001-0.65)              0.13(0.02-0.98)                     0.13                                                      
CD8+                                                                 0.14 (0.02-2.7)                0.31 (0.02-2.4)                     0.24                
       
Chronic GVHD                                                                                                   
       no or limited                                                        20 (63)                          35 (74)                                           
       extensive                                                              12 (37)                          12 (26)                          0.26                           
 
Chronic GVHD onset (days)                                                                      
after transplantation                                               127 (90-546)              137 (91-379)                         0.49 
median (range) 
 
Follow up days for surviving patients                  638 (225-825)             626 (384-873)                       0.72        
median (range) 
ANC=absolute neutrophil count, CMV=cytomegalovirus, GVHD=graft-versus-host disease 
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5.3.3. Acute GVHD and pDC 
Twenty-six (33%) of our patients developed grade II-IV acute GVHD at a median of 30 days 
and grade II-IV acute GVHD was found to be an independent predictor of pDC recovery.  
At day 100, we observed a significant decrease of total pDC in patients with grade II-IV acute 
GVHD when compared to patients without clinically significant acute GVHD (grades 0-I). 
(p<0.0001, Figure 13.) 
                                                                                                                                               
 
 
 
 
 
 
 
 
Figure 13. pDC stimulated with CpGA in patients with and without acute GVHD, p<0.0001 
 
Moreover, we observed that pDC stimulated with CpGA  in  patients with grade 0-I acute 
GVHD secreted significantly more IFN alpha and TNF alpha than pDC in patients with grade 
II-IV acute GVHD. (p=0.002 and p=0.0005, respectively, in Figure 14.)  
%
IF
N
a
lp
h
a
 o
f 
p
D
C
 w
it
h
 C
P
G
aG
vH
D
 0
-I
aG
vH
D
 II
-IV
0
10
20
30
40
%
T
N
F
a
lp
h
a
 o
f 
p
D
C
 w
it
h
 C
P
G
aG
vH
D
 0
-I
aG
vH
D
 II
-IV
0
20
40
60
 
Figure 14. IFN alpha and TNF alpha-secreting pDC stimulated with CpGA in patients with 
and without acute GVHD, p=0.002 and p=0.0005, respectively 
 
Similarly, in 46 patients the stimulation of PBMC was done with a TLR7 ligand R848, and 
here we also observed a significant decrease of total pDC in patients with grade II-IV acute 
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GVHD when compared to patients without clinically significant acute GVHD (grades 0-I).  
(p=0.001, Figure 15.) 
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Figure 15. pDC stimulated with R848 in patients with and without acute GVHD, p=0.001 
 
 
 
Finally, we also observed a decrease of IFN alpha-secreting, TNFalpha and IL6 secreting 
pDC in patients with grade II-IV acute GVHD when compared to patients without clinically 
significant acute GVHD (grades 0-I), even though it did not reach statistical significance. 
(p=0.22, p=0.08 and p=0.23, respectively, in Figure 16.) 
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Figure 16. IFN alpha, TNF alpha and IL6 -secreting pDC stimulated with R848 in patients 
with and without acute GVHD, p=0.22, p=0.08 and p=0.23, respectively 
 
 
Corticosteroids, either dexamethasone, prednisolone or methylprednisolone, do not affect DC 
viability but down-regulate the expression of costimulatory molecules on immature DCs, 
prevent DC maturation and impair their immunostimulatory activities.
197-202
 
Therefore we excluded the patients who received high doses of corticosteroid treatment (at 
least 1 mg/kg) at day 100 after allogeneic stem cell transplantation and reanalysed the pDC 
count and function in 58 patients. In concordance with previous studies, in our study the 
viability of pDC in patients was similar in both patients with and without corticosteroid 
therapy. We still saw a significant decrease of total pDC in patients with grade II-IV acute 
GVHD when compared to patients without clinically significant acute GVHD (grades 0-I). (p 
= 0.05 when stimulated with pDC and p = 0.01 when stimulated with R848, Figure 17.) 
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Figure 17. Total pDC count without patients who received high doses of corticosteroids 
(p=0.05 and p=0.01, respectively) 
 
On the contrary, in the analysis without the patients treated with high doses of corticosteroids 
at day 100, we did not observe any significant difference in the function of pDC between the 
groups of patients with and without clinically severe GVHD. Patients without acute GVHD or 
grade I acute GVHD before day 100 secreted similar amounts of IFN alpha, TNF alpha and 
IL6 as patients with grade II-IV acute GVHD. (in both conditions- stimulation with CpGA 
and R848, data not shown). 
5.3.4. pDC and chronic GVHD  
The cumulative incidence of extensive chronic GVHD in our study group was 37% (95%CI 
25-49%) at 20 months, with this incidence being higher in the “low pDC” recovery group 
(44%, 95% CI 24-63%) than in the “high pDC” recovery group (30%, 95% CI 17-46%) all 
though this did not reach statistical significance (p=0.25, Figure 18.) 
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Figure 18. Cumulative incidence of extensive chronic GVHD in the “low pDC” group of 
44% (95% CI 24-63%) at 20 months and in the “high pDC” group of 30% (95% CI 17-
46%), p=0.25 
 
 
 
5.3.5. pDC and relapse  
Relapse related mortality in our patients was 35 (95% CI) at 20 months with this being 
significantly higher (p=0.018) in the “low pDC” recovery group patients (35%, 95% CI 16-
54%) than in the “high pDC” recovery group patients (9.5%, 95% CI 3-21%) and this is 
shown in Figure 19. 
 
„high pDC“ recovery group 
„low pDC“ recovery group 
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Figure 19. Cumulative incidence of  relapse in the “low pDC” group of 35% (95% CI 16-
54%) at 20 months and in the “high pDC” group of 9.5% (95% CI  3-21% ), p=0.018 
 
5.3.6. pDC and overall survival  
Finally, “high pDC” recovery group of patients showed significantly better (p=0.007) overall 
survival (86%, 95% CI 76-97%) when compared with the overall survival of the patients in 
the “low pDC” recovery group (55%, 95% CI 38-80%). Overall survival of both group of 
patients is shown in Figure 20.  
„high pDC“ recovery group 
„low pDC“ recovery group 
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Figure 20. Overall survival in “low pDC” group (55%, 95% CI 38-80%) and “high” pDC 
group (86%, 95% CI 76-97%); p=0.007 
 
5.3.7. pDC count is an independent predictor of overall survival  
Finally, a multivariate analysis was done and included all relevant variables from the 
univariate analysis with a p<0.20 (donor, age of the recipient, pDC count) or previously 
known risk factors (risk of the disease). In this analysis, both older age of recipient and “low 
pDC” count stayed independent predictive factors of worse overall survival (p=0.02 and 
p=0.03, respectively). (Table 5.) 
 
„low pDC“ recovery group 
„high pDC“ recovery group 
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Table 5. Multivariate analysis of predictors of overall survival 
 
Risk factor                                     Relative risk           Confidence interval              p 
 
“low pDC” count                                 3.41                           1.19-9.79                     0.02 
older age of recipient                          5.16                          1.15-23.14                    0.03 
donor type- MUD                                 2.11                           0.63-7.06                     0.23 
high risk disease                                   1.14                            0.43-2.98                    0.79 
MUD-matched unrelated donor 
5.4. Th subpopulations of lymphocytes in the blood of patients at day 100 after 
allogeneic stem cell transplantation 
5.4.1. Stimulation and analysis of Th1 and Th17 
The functional analysis of Th subpopulations was done from the same PBMC samples already 
used for functional analysis of pDC. Blood CD4+T cells producing IL17A, IL21, TNFalpha 
and IFNgamma have been evaluated after 4.5 hours of stimulation of PBMC with PMA and 
ionomycine. The cells were first stained with the superficial markers CD3, CD4 and CD8, 
along with the FVD, a marker of viability. Unfortunately, we soon noticed that after 
stimulation only half of thawed cells stayed viable. This finding prevented us from 
performing an adequate flow cytometry because of the initial number of thawed cells 
available for this experiment. More precisely, as we already used about a million of PBMC 
for functional analysis of pDC for every condition and as we had 3 million of thawed cells per 
whole sample on average, we came to the conclusion that the available quantity of cells is not 
sufficient for the functional analysis of both lymphocytes and pDC at the same time. 
Therefore we decided to perform the functional analysis of only pDC from our samples, as it 
is a rare, controversial population of cells, especially in the GVHD setting. We analysed pDC 
together with the secretion of intracellular cytokines in three conditions of stimulation through 
TLR receptors. At the same time we evaluated only the number of Th1 and Th17 cells by 
staining the PBMC for eight specific cell surface markers; CD3, CD4, CD8, CCR6, CCR10, 
CD161 and CXCR3. 
Th17 cells have been found to express the mucosal chemokine receptor CCR6 but not 
CCR10.
203,204
 However, we had to exclude CCR10 antibody conjugated with PE because of 
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the problems with the compensation of fluorophores with the overlapping emission spectra 
(PE conjugated to CCR10 and FITC conjugated to CCR6). For this reason here we could not 
count the Th17 subpopulation by counting CCR6+CCR10-CD4+ T cells. 
However, as CD161 is the hallmark of Th17 cells as well as CXCR3 of IFN gamma secreting 
cells
205
, we were finally able to evaluate the absolute numbers of these two subpopulations of 
lymphocytes in the peripheral blood of our patients at day 100 after transplantation. (example 
or flow cytometry analysis in Figure 21.) The isotype controls served as negative control and 
we used 3 healthy donors as positive controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
50 
 
 
 
 
 
 
 
 
Figure 21. Flow cytometry analysis of Th17 and Th1 cells; Th cells were detected among 
mononuclear cells (A) as CD3+ (B) CD4+ (C) cells; CD3+CD4+cells and CD3+CD8+ cells 
were further evaluated for  specific surface markers CCR6, CD161 and CXCR3 (D) 
 
5.4.2 Th17 and acute GVHD 
Similarly as in pDC, we observed a decrease of the percentages of both CD161+CD4+ T cells 
and CXCR3+CD4+ T cells at day 100 in patients who had already developed acute GVHD. 
(Figure 22.) This decrease became significant when the absolute number of these cells was 
correlated with acute GVHD severity. Patients who had developed grade II-IV acute GVHD 
A 
C 
D 
B 
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had significantly lower percentages of both CD161+ Th cells as well as CXCR3+ (IFN 
gamma producing) Th cells when compared to patients with no acute GVHD or with grade I 
acute GVHD. (p = 0.009 and p = 0.029, respectively in Figure 23.) 
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Figure 22. CD161+ Th cells and CXCR3+ Th cells in patients with and without acute 
GVHD, p = 0.12 and p = 0.33, respectively 
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Figure 23. CD161+ Th cells and CXCR3+ Th cells in patients with grade 0-I acute GVHD 
compared to patients with grade II-IV acute GVHD, p = 0.009 and p = 0.029, respectively 
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5.4.3. Th17 and chronic GVHD 
Median value of the Th17 cells at day 100 after allogeneic stem cell transplantation was 24% 
of PBMC. We used this value to allocate the patients into a low or a high Th 17 group in order 
to define a predictive value for the chronic GVHD development. Baseline demographics of 
these two groups were comparable and are shown in Table 6. 
 
Table 6. Baseline demographic characteristics of “low”and “high” Th group 
 
 
Characteristic                                                         “low Th17”                    “high Th17”  
                                                                                      n (%)                              n (%)                     p-value 
                                                                                      n=40                                n=39                                 
Patient age, median (range)                                      54 (27-71)                      54 (25-69)                      0.94 
                                                   
Patient gender 
      Male                                                                      19 (48)                             21 (54)                        0.50                                                                                                           
      Female                                                                   21 (53)                             18 (46)                                
                                                                                      
Diagnosis 
      Myeloid malignancy                                             20 (50)                             22 (56)                                                          
         
Lymphoid malignancy                                          18 (45)                             17 (44)                                                                       
      Aplastic anemia                                                      2 (5)                                                                  0.66      
 
Disease risk 
      Standard risk                                                          24 (60)                            24 (62)                        
      High risk                                                                16 (40)                            15 (48)                        0.98                          
 
Conditioning regimen 
      Myeloablative                                                          6 (15)                               3 (8)                                       
      Reduced-intensity conditioning                34 (85)                            36 (92)                        0.28                                       
 
GVHD prophylaxis 
      CsA alone                                                              12 (30)                            14 (36)                                
      CsA and MMF /MTX                                            28(70)                             25 (64)                        0.47        
 
Donor gender 
      Male                                                                       25 (63)                            26 (67)                                                                                                        
      Female                                                                   15 (37)                            13 (33)                        0.82                                                   
 
CMV serologic status, seronegative pair 
      Yes                                                                        12 (30)                              9 (23) 
      No                                                                          28 (70)                            30 (77)                        0.45 
 
Donor type   
      Matched related donor                              18 (45)               19 (49) 
      Matched unrelated donor                                       12(30)                             14 (36)         
      Mismatched unrelated donor                                 10 (25)                              6 (15)                       0.51              
Stem cell source 
      Bone marrow                                                          7 (18)                                3 (8)                                                                                                                                             
      Peripheral blood                                                    25(63)                             31 (79)                                                        
      Cord blood                                                              8 (19)                              5(13)                         0.21                                  
         
CMV= cytomegalovirus, CsA=cyclosporine A, MMF=mycophenolate mofetil, MTX=methotrexate 
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As shown before, the cumulative incidence of chronic extensive GVHD was 37% (95%CI 25-
49%) at 20 months in the whole study group. When we separated our patients into a “low 
Th17” and “high Th17” group we found significantly higher incidence of chronic extensive 
GVHD in the “low Th17” group (53%, 95%CI 33-70%) than in the “high Th17” group (18%, 
95% CI 7-34%) with a p-value 0.01 (Figure 24.) 
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Figure 24. Cumulative incidence of extensive chronic GVHD in the “low Th17” group of  
(53%, 95%CI 33-70%) at 20 months and in the “high Th17” group of (18%, 95% CI 7-
34%), p=0.01 
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5.4.4. Univariate analysis of predictive factors for extensive chronic GVHD 
A cumulative incidence method was used in the univariate analysis of risk factors for the 
development of extensive chronic GVHD.  Low count of Th17 in blood of patients at day 100 
after allogeneic stem cell transplantation and development of clinically severe grade II-IV 
acute GVHD before day 100 (Figure 24. and Figure 25.) were associated with a significantly 
higher cumulative incidence of extensive chronic GVHD (p=0.01 and p=0.02, respectively). 
Female donor was also associated with a higher cumulative incidence of extensive chronic 
GVHD (p=0.13, Figure 26.) 
 
 
 
Figure 25. Cumulative incidence of  extensive chronic GVHD in the group of  patients with 
clinically severe aGVHD of 57% (95%CI 32-76%) at 20 months and in the group of 
patients without aGVHD of 26% (95%CI 14-40%), p=0.02 
 
Patients without or with grade I aGVHD 
Patients with grade II-IV aGVHD 
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Figure 26. Cumulative incidence of  extensive chronic GVHD in the group of  patients with 
female donor of 49% (95%CI 24-70%) at 20 months and in the group of patients with male 
donor of 31% (95%CI 17-46%), p=0.13 
 
 
5.4.5. Multivariate analysis of predictive factors for extensive chronic GVHD 
All variables with a p-value < 0.20 in the univariate analysis (the presence of grade II-IV acute 
GVHD, „low“ Th17 count and female sex of the donor) together with previously known 
predictive factors of chronic GVHD (unrelated donor, older age of recipient, peripheral blood as 
stem cell source and active disease) were included in the multivariate analysis in order to define 
predictive factors for the development of extensive chronic GVHD. 
         Female donor 
Male donor 
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In this analysis (Table 7.) only the low Th17 count stayed an independent predictor of 
development of extensive chronic GVHD. (RR 3.318, 95% CI 1.234-8.92, p = 0.017) 
 
 
 
Table 7. Multivariate analysis of predictors of risk factors of extensive chronic GVHD 
 
Risk factor                                     Relative risk             Confidence interval                   p 
 
“low Th17” count                              3.318                            1.234-8.92                         0.017 
female donor                                       2.180                            0.917-5.19                         0.078 
grade II-IV acute GVHD                     1.992                            0.863-4.60                        0.110                       
peripheral blood stem cells                 1.689                            0.650-4.39                         0.280 
active disease                                      0.773                            0.304-1.97                         0.590 
unrelated donor                                  1.159                             0.511-2.63                         0.720 
“older” age of recipient                      1.070                             0.396-2.89                         0.890 
 
 
5.5. Inflammatory cytokines in the serum of patients at day 100 after allogeneic stem cell 
transplantation 
Using a Luminex Xmap system from one serum of each patient taken at day 100 after 
allogeneic stem cell transplantation we evaluated the concentrations of 41 cytokine: IL1a, 
IL1b, IL1ra, IL2, IL2ra, IL4, IL5, IL6, IL7, IL9, IL10, IL12p40, IL12p70, IL13, IL15, IL17, 
IL21, IL23, IL8 (CXCL8), IP10 (CXCL10), MCP1 (CCL2), MIP1a (CCL3), MIP1b (CCL4), 
RANTES (CCL5), MCP3 (CCL7), TARC (CCL17), MDC (CCL22), FRACTALKINE 
(CX3CR1), IL3 (multi-CSF), VEGF, PDGFABBB, TNFalpha, TNFbeta, TRAIL, CD40L, 
BAFF, IFNa2, IFN gamma,  ELAFIN, TGF alpha, FLT.3L. In this analysis we included 
serums from 152 patients taken at day 100 after allogeneic stem cell transplantation and 
evaluated the relation of concentrations of cytokines to the development and severity of 
chronic GVHD. 
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5.5.1. Patient characteristics 
This time study population included 79 patients already characterized plus additional 73 
patients who received allogeneic stem transplantation between years 2005 and 2008. Finally, 
the study population was similar, with 83 male patients (55 %) and 69 female patients (45%), 
and the median age of 49 years (range, 17-71 years). Donors were matched related in 70 cases 
(46%) and unrelated in 82 patients (54%). Source of stem cells was peripheral blood in 108 
cases (72%). Conditioning regimen was myeloablative in 48 transplantations (32%) and 
reduced-intensity in 104 (68%) transplantations. 77 patients (51%) had previously developed 
acute GVHD. 
With the median follow up of 16 months, 70 patients (46%) developed chronic GVHD after a 
median of 6 months. This led to a cumulative incidence of chronic GVHD of 52% at 2 years 
and cumulative incidence of extensive chronic GVHD of 38% at 2 years. 46 patients (30%) 
developed limited chronic GVHD and 24 patients (16%) developed extensive chronic GVHD.  
By making histogrammes of cytokine levels at day 100 after allogeneic stem cell 
transplantation in our patients, we saw a degenerated distribution of eight cytokines (IL1b, 
IL1ra, IL5, IL12p70, IL13, IL21, IL23 and TNF beta) that made us exclude these cytokines 
from further analysis. The caracteristics of the resting cytokines are presented in the Table 8. 
5.5.2. Significant cytokines at day 100 for the development of chronic GVHD 
In univariate analysis (using a cumulative incidence method) we analized 33 cytokines and 
found 22 cytokines to be significative with a p < 0.20. (Table 8.) 
Univariate analysis for risk factors associated with chronic GVHD is shown in Table 9. Eight 
factors were evidently different between subgroups with and without chronic GVHD (p < 
0.20), but four risk factors emerged as clinically significant- sex and age of the recipient, 
number of CD34+ cells infused and previous acute GVHD. Male patients had 1.5 times 
higher chance of chronic GVHD (p = 0.083), patients older than 35 years had 2.2 times higher 
chance of chronic GVHD than younger patients (p = 0.065), patients who received more than 
8.8 x 10
6 
CD34+ cells had 1.9 times higher risk of chronic GVHD (p = 0.019), and the 
patients who have had acute GVHD previously, had a 1.9 times higher chance of chronic 
GVHD. (p = 0.012). A multivariate analysis was done next to define the cytokines related to 
the development of chronic GVHD independently of risk factors for chronic GVHD. (Table 
10.) Finally, we defined 8 cytokines related to the development of chronic GVHD; IL10, 
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IL15, IP10, TNF alpha and FLT.3L seemed to increase the chance of chronic GVHD, while 
TARC, MDC and FRACTALKINE seemed to decrease the chance of chronic GVHD. 
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Table 8. Univariate analysis of 33 cytokines related to chronic GVHD 
 
Cytokines N N_0 N_1 average.
+ 
e.t.+ min+ max+ threshol
d 
HR p-
value 
IP10 152 93 59 2499,48 4101,53 2,92 24244,34 1448,42 3,09 <0,000
1 
FLT.3L 152 84 68 94,78 115,23 4,02 903,54 70,29 2,43 0,0002 
IL15 152 109 43 3,61 7,70 1,67 90,14 2,61 2,42 0,0004 
MDC 152 40 112 1431,89 1723,47 49,34 10053,35 504,97 0,41 0,0004 
IL3 152 91 61 10,33 13,34 1,45 75,88 7,25 2,22 0,0007 
IL10 152 48 104 14,39 38,73 2,08 433,61 2,08 2,57 0,0015 
TARC 152 32 120 1236,32 1953,70 4,97 5144,85 60,56 0,49 0,0054 
RANTES 151 74 77 41311,25 24703,62 1458,0
0 
93825,00 41100,00 0,51 0,0056 
IL2ra 152 51 101 506,22 938,44 7,72 8522,69 141,10 2,05 0,0089 
FRACT-
ALKINE 
152 67 85 65,17 229,67 6,79 2400,55 12,91 0,60 0,0315 
IL12p40 152 119 33 26,30 64,83 2,51 739,95 37,61 0,51 0,0456 
MIP1a 152 88 64 26,54 20,35 3,18 97,53 24,68 0,61 0,0471 
TNFa 152 97 55 12,01 7,65 0,76 49,25 12,70 1,60 0,0493 
TRAIL 152 77 75 23,16 25,22 4,85 120,46 12,15 0,66 0,0817 
PDGF-
ABBB 
152 25 127 8235,88 3073,73 1,05 9847,81 4122,41 0,59 0,0830 
IL6 152 92 60 8,07 14,51 0,89 102,30 3,59 1,50 0,0872 
IFN-
gamma 
152 97 55 18,80 30,68 2,12 240,54 11,26 0,64 0,0944 
MCP1 152 75 77 758,42 857,74 2,27 4540,87 468,00 1,49 0,0988 
ELAFIN 151 91 60 10028,51 8492,81 870,00 53650,00 8917,00 1,44 0,1274 
MIP1b 152 133 19 65,95 48,73 2,21 462,45 108,29 0,50 0,1325 
IL1a 152 118 34 15,39 45,29 3,76 362,06 4,00 0,65 0,1736 
TGF-
alpha 
152 129 23 8,34 9,60 0,85 88,56 12,29 1,48 0,1960 
IL17 152 90 62 5,66 15,40 0,60 120,19 0,60 0,73 0,2163 
IL8 151 125 26 40,37 34,54 0,42 260,39 57,78 1,41 0,2634 
VEGF 152 109 43 153,83 208,29 10,57 1996,39 165,97 1,32 0,2754 
CD40L 152 16 136 8806,31 2850,88 2,95 10009,50 2417,11 1,66 0,3223 
IL2 152 136 16 1,88 7,08 0,54 77,47 1,75 1,44 0,3320 
BAFF 151 89 62 3566,80 2194,90 379,00 11960,00 3739,00 0,79 0,3467 
IFN-
alpha2 
152 126 26 8,99 12,11 4,15 78,01 12,33 1,33 0,3495 
MCP3 152 111 41 9,79 16,55 5,67 167,97 5,67 0,80 0,4419 
IL7 152 134 18 2,59 3,59 1,34 26,54 4,42 1,26 0,5143 
IL9 152 128 24 3,42 4,33 2,31 39,53 2,79 1,22 0,5514 
IL4 152 136 16 13,55 31,94 5,96 250,42 15,98 0,80 0,5804 
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Table 9. Univariate analysis of risk factors for chronic GVHD 
Risk factor HR p-value 
Acute GVHD (Yes vs. No) 1,9 0,012 
Number of CD34 (More than 8,8 vs.Less) 1,9 0,019 
Age of recipient (More than 35 years vs.Younger) 2,2 0,065 
Sex of the recipient 1,5 0,083 
CMV serology of recipient (Positives vs. Negatives) 1,5 0,109 
Type of the donor (Siblings vs. Others) 0,7 0,148 
CMV serology of donor (Positives vs. Negatives) 0,7 0,161 
Source of the transplant ("PB infused" vs. Other) 1,4 0,195 
Type of disease (Myeloid vs.Other) 0,8 0,391 
GVHD prophylaxis (Dual vs.Other) 1,1 0,573 
Sex of the donor (Males vs. Females) 1,1 0,641 
Disease status (CR vs. Other) 0,9 0,659 
Type of conditioning (Myeloablatives vs. RIC) 0,9 0,7 
 
 
 
Table 10. Multivariate analysis of cytokines to the development of chronic GVHD, 
indepedent of risk factors 
Cytokines Threshold N HRa_ Pvalue (HRa) p-value 
(pH+) 
IP10 1448,42 151 3,13 <0,0001 0,8987 
FLT.3L 70,29 151 2,11 0,0032 0,9391 
FRACTALKINE 12,91 151 0,54 0,0125 0,7806 
IL15 2,61 151 2,00 0,0144 0,7319 
MDC 504,97 151 0,54 0,0192 0,8081 
TNFalpha 12,70 151 1,76 0,0200 0,9422 
IL10 2,08 151 2,03 0,0329 0,3948 
TARC 60,56 151 0,58 0,0438 0,2459 
IL3 7,25 151 1,63 0,0607 0,6348 
PDGFABBB 4122,41 151 0,56 0,0707 0,1800 
RANTES 41100,00 150 0,64 0,0926 0,8223 
IL12p40 37,61 151 0,57 0,1141 0,9133 
IL1a 4,00 151 0,60 0,1141 0,8867 
IL2ra 141,10 151 1,59 0,1142 0,3548 
MCP1 468,00 151 1,44 0,1352 0,2166 
TGFa 12,29 151 1,58 0,1480 0,0116 
MIP1a 24,68 151 0,70 0,1585 0,8417 
IFNgamma 11,26 151 0,69 0,1691 0,9626 
TRAIL 12,15 151 0,72 0,1741 0,3059 
IL6 3,59 151 1,39 0,1799 0,4129 
MIP1b 108,29 151 0,59 0,2630 0,7228 
ELAFIN 8917,00 150 1,18 0,5343 0,6741 
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5.5.3. Significant cytokines at day 100 for the development of extensive chronic GVHD 
In this analysis we included only the patients who developed extensive chronic GVHD, more 
precisely- the patients who developed limited chronic GVHD were included in the no GVHD 
group. In the univariate analysis (using a cumulative incidence method) we found 25 
cytokines to be significative with a p < 0.20. (Table 11.) Univariate analysis for risk factors 
associated with extensive chronic GVHD defined six significant risk factors with a p < 0.20, 
and previous acute GVHD, source of the transplant and number of CD34+ infused cells 
emerged as clinically significant. (Table 12.) Finally, a multivariate analysis was done to 
define the cytokines related to the development of extensive chronic GVHD but indepedently 
of the three clinical risk factors defined for the extensive chronic GVHD. In this analysis 10 
cytokines emerged as significant; IL2, IL2ra, IL10, IP10, MIP1b seemed to increase the 
chance of extensive chronic GVHD, while IL12p40, RANTES, TARC, MDC, 
FRACTALKINE seemed to decrease the chance of extensive chronic GVHD. (Table 13.) 
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Table 11. Univariate analysis of 33 cytokines related to extensive chronic GVHD 
Cytokines N N_0 N_1 average.+ e.t.+ min+ max+ threshold HR p-value 
MDC 152 40 112 1431,89 1723,47 49,34 10053,35 504,97 0,29 <0,0001 
IL10 152 101 51 14,39 38,73 2,08 433,61 8,97 2,94 0,0001 
IP10 152 84 68 2499,48 4101,53 2,92 24244,34 1166,34 2,97 0,0002 
IL15 152 131 21 3,61 7,70 1,67 90,14 5,38 2,98 0,0010 
TARC 152 81 71 1236,32 1953,70 4,97 5144,85 244,40 0,39 0,0025 
FLT.3L 152 84 68 94,78 115,23 4,02 903,54 70,29 2,30 0,0038 
IL3 152 92 60 10,33 13,34 1,45 75,88 7,64 2,28 0,0040 
RANTES 151 74 77 41311,25 24703,62 1458,00 93825,00 41100,00 0,42 0,0045 
IL12p40 152 85 67 26,30 64,83 2,51 739,95 13,32 0,41 0,0080 
FRACTA-
LKINE 
152 63 89 65,17 229,67 6,79 2400,55 11,25 0,50 0,0151 
IFNgamma 152 46 106 18,80 30,68 2,12 240,54 3,43 0,51 0,0207 
IL2ra 152 71 81 506,22 938,44 7,72 8522,69 231,04 1,99 0,0217 
TRAIL 152 130 22 23,16 25,22 4,85 120,46 50,09 1,93 0,0512 
MIP1b 152 77 75 65,95 48,73 2,21 462,45 57,06 1,72 0,0652 
BAFF 151 91 60 3566,80 2194,90 379,00 11960,00 3804,00 0,55 0,0663 
TGFa 152 22 130 8,34 9,60 0,85 88,56 1,69 0,53 0,0725 
MCP1 152 18 134 758,42 857,74 2,27 4540,87 253,63 0,52 0,0887 
IL8 151 82 69 40,37 34,54 0,42 260,39 34,61 1,62 0,1008 
IL2 152 136 16 1,88 7,08 0,54 77,47 1,75 1,92 0,1073 
PDGFABBB 152 25 127 8235,88 3073,73 1,05 9847,81 4122,41 0,57 0,1259 
MIP1a 152 88 64 26,54 20,35 3,18 97,53 24,68 0,64 0,1485 
ELAFIN 151 109 42 10028,51 8492,81 870,00 53650,00 10667,00 1,53 0,1589 
IL6 152 93 59 8,07 14,51 0,89 102,3 3,68 1,48 0,1823 
IL9 152 136 16 3,42 4,33 2,31 39,53 4,13 0,40 0,1929 
TNFalpha 152 136 16 12,01 7,65 0,76 49,25 19,97 0,40 0,1948 
VEGF 152 109 43 153,83 208,29 10,57 1996,39 165,97 1,44 0,2242 
MCP3 152 133 19 9,79 16,55 5,67 167,97 10,87 1,53 0,2957 
IL17 152 90 62 5,66 15,40 0,60 120,19 0,60 0,75 0,3435 
IL7 152 117 35 2,59 3,59 1,34 26,54 1,34 0,70 0,3519 
IFNa2 152 108 44 8,99 12,11 4,15 78,01 4,34 1,29 0,4111 
CD40L 152 24 128 8806,31 2850,88 2,95 10009,50 7043,93 0,77 0,5075 
IL1a 152 135 17 15,39 45,29 3,76 362,06 18,71 0,72 0,5348 
IL4 152 130 22 13,55 31,94 5,96 250,42 8,67 1,18 0,6748 
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Table 12. Univariate analysis of risk factors for extensive chronic GVHD 
Risk factor HR p-value 
Acute GVHD (Yes vs No) 2,3 0,009 
Source of the transplant ("PB infused" vs. Other) 2,6 0,019 
Number of CD34 (More than 0,4 vs. Less) 7 0,054 
Age of recipient (More than 35 years vs.Younger) 2,2 0,127 
Sex of the recipient 1,5 0,15 
Type of the donor (Siblings vs. Others) 1,1 0,171 
CMV serology of recipient (Positives vs. Negatives) 1,4 0,218 
Type of disease (Myeloid vs.Other) 0,8 0,437 
Disease status (CR vs Other) 0,8 0,48 
Type of conditioning (Myeloablatives vs. RIC) 1,1 0,769 
CMV serology of donor (Positives vs.Negatives) 1 0,87 
GVHD prophylaxis (Dual vs.Other) 1 0,921 
Sex of the donor (Males vs. Females) 1 0,942 
 
 
 
Table 13. Multivariate analysis of cytokines to the development of extensive chronic 
GVHD, indepedent of risk factors 
Cytokines Threeshold N HRa_ p-value (HRa) p-value (pH+) 
IP10 1166,34 151 3,00 0,0003 0,5906 
MDC 504,97 151 0,43 0,0103 0,7040 
FRACTALKINE 11,25 151 0,47 0,0110 0,9492 
IL10 8,97 151 2,09 0,0193 0,4118 
IL2ra 231,04 151 2,04 0,0212 0,1836 
RANTES 41100,00 150 0,47 0,0214 0,5811 
MIP1b 57,06 151 1,90 0,0315 0,5459 
TARC 244,40 151 0,51 0,0389 0,8166 
IL12p40 13,32 151 0,48 0,0417 0,1160 
IL2 1,75 151 2,32 0,0478 0,7293 
IFNgamma 3,43 151 0,57 0,0597 0,0389 
FLT.3L 70,29 151 1,76 0,0701 0,6670 
TGFa 1,69 151 0,53 0,0821 0,1964 
IL15 5,38 151 1,87 0,0923 0,3436 
BAFF 3804,00 150 0,61 0,131 0,5073 
IL3 7,64 151 1,60 0,1311 0,6893 
PDGFABBB 4122,41 151 0,57 0,1327 0,0643 
MCP1 253,63 151 0,57 0,1467 0,9683 
IL6 3,68 151 1,41 0,2499 0,9248 
ELAFIN 10667,00 150 1,40 0,2801 0,8500 
TRAIL 50,09 151 1,44 0,3020 0,6001 
IL9 4,13 151 0,49 0,3233 0,5347 
IL8 34,61 150 1,34 0,3374 0,3649 
TNFalpha 19,97 151 0,57 0,4625 0,4620 
MIP1a 24,68 151 0,82 0,5266 0,3550 
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5.5.4. A prognostic score for the development of chronic GVHD  
Using the multivariate Cox model combined with the statistical approach called “time-
dependent ROC curves” we tried to establish a practical prognostic score for the development 
of chronic GVHD. All the parameters that were found to be significant in the univariate 
analysis (p<0.20) were included in the calculation of the score and the score was finally 
composed of 30 parameters – eight clinical factors and 22 cytokines. (Table 14.) For every 
patient the score was calculated as a sum of coefficients (logarithms of relative risks) for 
every risk factor multiplied with 1 if the parameter was equal or higher than the threshold or 
with 0 if not. Accordingly, when the coefficient was positive, the score and the risk of chronic 
GVHD augmented when the factor was 1. In the contrary, if the coefficient was negative, the 
score and the risk of chronic GVHD decreased when the factor was 1. Further on, we 
evaluated this scoring system and its predictive value by using the ROC curves, shown in the 
Figure 27. 
The first histogram shows the problem of overfitting and overestimation of the predictive 
power if there are no corrections (AUC=0.96, 95%CI, 0.93-0.99). On the contrary, cross-
validation by bootstrap underestimates the prognostic power (AUC=0.77, 95% CI, 0.63-0.89). 
The last graph is based on 0,632 bootstrap resampling method for repeated cross-validation, 
and is the most interesting with the AUC 0.80 (95%CI, 0.70-0.89). 
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Table 14. Prognostic score for the development of chronic GVHD 
Parametres Coef. CI95%inf. CI95%sup. Value 
IP10 2,23916112 0,79759320 4,23724068 1  if  IP10>1448,42 
FLT.3L 0,40374927 -1,53750513 2,05893911 1 if FLT.3L>70,29 
IL15 1,18686042 -0,74788538 3,57690213 1 if IL15>2,61 
MDC -1,87466497 -4,15841103 0,02710002 1 if MDC>504,97 
IL3 0,83257559 -0,77387295 2,62119197 1 if IL3>7,25 
IL10 -0,61229720 -2,66460604 1,09402341 1 if IL10>2,08 
TARC 1,16168225 -0,60674783 3,42480191 1 if TARC>60,56 
RANTES -0,45332960 -2,06756804 0,97900221 1 if RANTES>41100,00 
IL2ra -0,37738579 -2,12602193 1,39214229 1 if IL2ra>141,10 
FRACTALKINE -0,70487796 -2,26464985 0,70393524 1 if  FRACTALKINE>12,91 
IL12p40 -2,21646362 -4,37689538 -0,64984374 1 if IL12p40>37,61 
MIP1a -0,81412769 -2,54714373 0,58623723 1 if MIP1a>24,68 
TNFalpha 1,29784277 -0,21616966 3,61206427 1 if TNFa>12,70 
TRAIL -0,86428069 -2,19104771 0,40640364 1 if TRAIL>12,15 
IL6 0,86064206 -0,70139761 2,48980162 1 if PDGFABBB>4122,41 
IFNgamma -0,72052015 -2,43529138 0,81057035 1 if IL6>3,59 
MCP1 1,18352587 -0,02360060 2,62437113 1 if IFNgamma>11,26 
ELAFIN -0,42643423 -2,24982683 1,15489178 1 if MCP1>468,00 
MIP1b -1,51953280 -3,59925344 0,30048601 1 if MIP1b>108,29 
IL1a -1,41822684 -3,15136537 0,12025628 1 if IL1a>4,00 
TGFa 0,96051419 -0,94231936 2,70213910 1 if TGFa>12,29 
Sex of Recipient 1,09819942 -0,31457606 2,80232758 1 if recipient is male 
Type of Donor 0,07893726 -1,11936261 1,42853186 1 if donor is identical sibling 
CMV Donor -0,78967092 -2,26220464 0,48160984 1 if recipient is CMV positive 
CMV Recipient 0,78343149 -0,60365179 2,27149181 1 if donor is CMV positive 
Source of Cells 0,27156417 -1,72166762 2,09964677 1 if PB infused 
Acute GVHD -0,16325185 -1,83509242 1,33543387 1 if acute GVHD before 
Age of Recipient 0,37478191 -1,70664429 2,79312051 1 if age of  recipient>35,00 
Number of CD34 0,39777467 -1,14524435 2,06809033 1 if CD34>8,80 
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Figure 27. Prognostic score for the development of chronic GVHD at 2 years after 
allogeneic stem cell transplantation; predictive power of 96% (95%CI 93-99%) if there are 
no corrections (A); predictive power of 77% (95% CI, 63-89%) estimated with cross-
validation by bootstrap (B); predictive power of 80% (95%CI, 70-89%) with the use of 0,632 
bootstrap resampling method for repeated cross-validation (C) 
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5.5.5. A prognostic score for the development of extensive chronic GVHD  
Using the same tests we tried to establish a similar prognostic score for the development of 
extensive chronic GVHD. All the parameters significant in the univariate analysis (p<0.20) 
(Table 15.) were included in the calculation of the score (31 parameter – six clinical variables 
and twenty five cytokines) and the ROC curves are shown in the Figure 28. The first 
histogram shows the problem of overfitting which is even more evident and overestimates the 
predictive power to 98% (AUC=0.98, 95%CI, 0.96-1.0). However, using the 0,632 bootstrap 
resampling method for repeated cross-validation, the AUC is 0.78 (95%CI, 0.66-0.88) and 
shows the power of the test in reality among the comparable but independent individuals. 
 
Table 15. The prognostic score for extensive chronic GVHD development 
Parametres Coef. CI95%inf. CI95%sup. Value 
MDC 0,26367659 -4,8337435 5,5303094 1 if MDC>504,97 
IL10 -0,19731159 -4,8977038 3,8524482 1 if IL10>8,97 
IP10 2,43238655 -1,3497585 7,9599239 1 if IP10>1166,34 
IL15 2,43678023 -2,0233360 7,9312229 1 if IL15>5,38 
TARC -0,52852715 -4,7447792 3,7705134 1 if TARC>244,40 
FLT.3L 0,34026638 -3,8500076 5,8886953 1 if FLT.3L>70,29 
IL3 0,84907886 -2,5964658 4,6315737 1 if IL3>7,64 
RANTES -1,15303387 -6,7333993 1,7969284 1 if RANTES>41100,00 
IL12p40 -2,33306453 -9,0162553 1,0591098 1 if IL12p40>13,32 
FRACTALKINE -2,14486388 -6,8269798 0,5762474 1 if FRACTALKINE>11,25 
IFNgamma -1,23429345 -6,8607339 1,9398523 1 if IFNgamma>3,43 
IL2ra 0,80002705 -4,2925700 5,7382398 1 if IL2ra>231,04 
TRAIL 0,82921537 -3,7890205 6,4874130 1 if TRAIL>50,09 
MIP1b 2,97522835 -0,3396939 12,0788208 1 if MIP1b>57,06 
BAFF -2,48149497 -9,5570088 1,1197671 1 if BAFF>3804,00 
TGFalpha -0,15994565 -5,2852718 5,4871899 1 if TGFalpha>1,69 
MCP1 -1,22616057 -7,6681998 5,2281949 1 if MCP1>253,63 
IL8 -1,41458658 -7,9819421 2,3840474 1 if IL8>34,61 
IL2 0,53327738 -4,0063708 5,2598009 1 if IL2>1,75 
PDGFABBB 0,17681959 -6,8965569 6,8507727 1 if PDGFABBB>4122,41 
MIP1a 0,04088765 -3,6220374 3,7556950 1 if MIP1a>24,68 
ELAFIN 1,94733210 -1,1841098 6,5251781 1 if ELAFIN>10667,00 
IL6 1,49156156 -2,3507186 6,8333935 1 if IL6>3,68 
IL9 -4,07205383 -22,0987445 5,1544495 1 if IL9>4,13 
TNFalpha -1,13177124 -21,1773142 7,9925181 1 if TNFalpha>19,97 
Sex of Recipient 0,21588724 -3,5736196 3,7790536 1 if recipient male 
Type of Donor 1,23695302 -1,8167660 4,9934955 1 if Identical sibling 
Source of cells 3,32039370 -1,2149629 11,8415079 1 if PB infused 
aGVHD 0,95830143 -3,4919826 4,9309722 1 if acute GVHD before 
Age of Recipient 0,72704734 -4,9769957 9,3507852 1 if Age recipient>35,00 
Number of CD34 20,83204323 13,5454600 33,7111661 1 if CD34>0,40 
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Figure 28. Prognostic score for the development of extensive chronic GVHD at 2 years 
after allogeneic stem cell transplantation; predictive power of 98% (95%CI 96-100%) if 
there are no corrections (A); predictive power of 72% (95% CI, 55-88%) estimated with 
cross-validation by bootstrap (B); predictive power of 78% (95%CI, 66-88%) with the use of 
0,632 bootstrap resampling method for repeated cross-validation (C) 
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6. Discussion 
6.1. The pDC recovery at day 100 in peripheral blood of transplanted patients is 
impaired by the development of clinically significant acute GVHD  
It has been previously shown
 
that both mDC and pDC recover quickly in the peripheral blood 
of patients after allogeneic stem cell transplantation and represent bone marrow recent 
emigrants since they reach their highest proportions among white blood cells in the earliest 
phase of immune reconstitution.
114 
However, patients recover to the pretransplant mDC and 
pDC levels within day +60 after allogeneic stem cell transplantation but do not reach a normal 
absolute number in the blood until one year after allogeneic stem cell transplantation.
120
 The 
release kinetics of DC is found to be more rapid in patients treated with G-CSF, but their 
count decreases gradually after G-CSF withdrawal and reaches the values similar to patients 
untreated with G-CSF. Furthermore, the source of stem cells does not seem to influence mDC 
recovery either but the level of pDC is significantly decreased in the blood of patients who 
receive bone marrow instead of peripheral blood stem cells. Moreover, DC recovery may be 
faster after RIC as compared to myeloablative preparatory regimens.
206 
Finally, patients with 
acute GVHD present with a less rapid DC recovery on day +30 and on day +100 than patients 
without acute GVHD. 
Our study evaluated pDC proportions in the peripheral blood of patients at day +100 after 
allogeneic stem cell transplantation and analyzed all relevant clinical parameters related to 
this counts. The recovery of pDC in our study was not influenced by the patients' or graft  
characteristics, conditioning regimen or infections, as it has been shown before. On the 
contrary, in our group of patients, only the occurence of grade II-IV acute GVHD in the 
multivariate analysis was found to be significantly associated with an impaired pDC recovery. 
However, treatment with corticosteroids has been shown to efficiently deplete pDC from the 
blood of transplant recipients
207
 as well as healthy donors.
197
 Since the glucocorticoids 
represent the standard treatment of grade II-IV acute GVHD in our institution, it is possible 
that the drop in the pDC level at day +100 in our group of patients was at least in part due to 
the corticosteroids and not only to acute GVHD itself. It has been shown before
114
 that 
number of pDC even increases in the blood during the early phase of acute GVHD and 
consistently and significantly decreases soon after the beginning of therapy with steroids.  
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Our data would be in concordance with the finding that the reconstitution of blood pDC levels 
in patients after allogeneic stem cell transplantation can be delayed because of clinically 
significant acute GVHD and its treatment with corticoids.
198
  
6.2. Corticosteroids have a deleterious impact on the function of pDC, but do not affect 
their viability 
Together with the finding of a significant decrease of pDC count in patients with grade II-IV 
acute GVHD in comparison to patients without clinically significant acute GVHD, we also 
observed a significant decrease of functional pDC (IFN alpha and TNF alpha-secreting pDC) 
in patients with clinically significant grade II-IV acute GVHD when compared to patients 
with grade 0-I acute GVHD. 
As mentioned before, all our patients with grade II-IV acute GVHD were treated with high 
doses of corticosteroids (2 mg/kg) at the time of GVHD ocurrence and, if an adequate 
response was observed, the dose was rapidly tappered down. Consequently, the lower pDC 
proportion in grade II-IV acute GVHD could partially be related to the imunosupressive 
treatment. 
Therefore we reanalyzed our results by excluding the patients who were still receiving high 
doses of corticosteroids at day +100 after allogeneic stem cell trasplantation. This left out 21 
patients from our study group for further analysis. In the new study group, we still saw a 
significant decrease of total pDC in patients with grade II-IV acute GVHD when compared to 
patients without clinically significant acute GVHD (grades 0-I). Therefore we presumed that 
the lower pDC proportions in the peripheral blood of our patients at day +100 were directly 
associated to the development of the acute GVHD, and not to the corticosteroid treatment 
itself. 
However, in the new functional analysis of activated pDC, without the patients under the 
treatment of corticosteroids, we did not see a significant decrease of IFN alpha, TNF alpha 
and IL6-secreting pDC. This finding suggested that the resting pDC in the blood of patients 
were functionally less activated because of the corticosteroid treatment. This observation is in 
concordance with previous studies where corticosteroids seemed to prevent DC maturation 
and impair their immunostimulatory activities even though they did not affect DC viability.
199-
202
  
As it is known that residual host DC after conditioning regimen
107-109
 are crucial in initiating 
acute GVHD, we could here hypothesize that administering corticosteroids to patients shortly 
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before the beginning of the conditioning regimen might selectively inactivate recipients' DC 
and thus reduce the risk of acute GVHD. 
6.3. The reduced pDC number in peripheral blood of transplanted patients correlates 
with clinically significant acute GVHD 
A possible mechanism underlying the decrease in the number of pDC in the peripheral blood 
at day +100 in patients with clinically significant acute GVHD might be the recruitment of 
pDC from the peripheral blood to the affected tissuses during the occurrence of acute GVHD. 
In accord with this assumption, in a previous study from our study group
208
 we determined 
proportions of pDC in intestinal biopsies in patients with and without acute GVHD. This 
study showed a significant increase of CD123+ pDC in the intestinal mucosa of patients with 
acute GVHD compared with mucosa of patients without acute GVHD. Furthermore, the 
number of CD123+cells paralleled the histological grade of acute GVHD (the higher the 
grade, the higher was the number of pDC). The recruitment of pDC to inflammatory lesions 
of target tissues is not exclusively related to GVHD, but it has also been shown in several 
autoimmune diseases, as systemic lupus erythematosus.
85
 
On the other hand, a tolerogenic potential of human pDC has already been suggested, and it 
has been proposed that pDC might be responsible for the induction and maintenance of self-
tolerance. It has been shown that antigen-specific CD4 T-cell lines in humans become anergic 
when exposed to immature pDC previously pulsed with specific antigen.
209
 CCR9+pDC were 
identified as tolerogenic pDC capable of inhibiting acute GVHD by inducing Tregs.
113
 In this 
context, a reduced pDC number in the blood of our patients with clinically significant acute 
GVHD provides evidence for the concept that resting pDC in the blood are tolerogenic and 
have the potential to prevent GVHD. This is in concordance with the finding that our patients 
with severe acute GVHD had also lower proportions of IFN alpha and TNF alpha-secreting 
pDC than the patients without clinically significant acute GVHD. 
In summary, we have demonstrated that pDC decrease in the peripheral blood of patients with 
severe acute GVHD. However, since we did not analyze the proportions of pDC in the GVHD 
target tissues, we cannot conclude whether activated pDC migrated to the acute GVHD 
organs and have a role in maintenance of acute GVHD or if reduced numbers of tolerogenic 
pDC in blood may correlate with enhanced donor T-cell responses thus promoting GVHD, as 
it has been proposed before.
210
 Consequently, we conclude that the role of pDC in promoting 
or supressing GVHD should also be evaluated in the context of their activation status.  
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6.4. The reduced pDC number in peripheral blood of transplanted patients is an 
independent predictor of worse long-term outcome of patients 
Given the central role of DC in the immune system, several previous studies have 
hypothesized that the recovery of DC after allogeneic stem cell transplantation could be 
related to long-term outcome of patients' relapse and survival. Reddy et al.
115
 measured 
circulating DC in the peripheral blood at engraftment with a presumption that this represents 
the earliest period of donor immune reconstitution and found that low mDC count was 
independently associated with death, time to relapse and acute GVHD, while low pDC 
number was associated with acute GVHD only. 
Mohty et al.
116
 evaluated pDC count in the peripheral blood of 54 patients at the third month 
after reduced-intensity conditioning HLA-identical sibling allogeneic stem cell transplantation 
and separated the patients according to the pDC recovery profile  into a „high“ and „low“ 
pDC group. In this study, „high“ pDC group had an improved overall survival in comparison 
to the „low“ pDC group due to the higher non-relapse mortality, notably from GVHD and late 
infections. In contrast, patients from the „low“ and „high“ pDC group had comparable rates of 
relapse and this was explained by a high predominance of high-risk patients with a high-
tumor burden in the study group. In a multivariate analysis, a „high“ PDC count stayed an 
indepedent factor predictive of a decreased risk of death and this result suggested that 
quantification of pDC at 3 months after transplantation could be a simple but useful tool for 
predicting patients' outcome. 
In our study we wanted to further evaluate the pDC count at day +100 after allogeneic stem 
cell transplantation as an indicator of long term outcome. 
By allocating the patients according to the median value of pDC at day +100 we obtained two 
comparable groups according to demographic and transplant characteristics, as well as 
transplant related events, except of the acute GVHD. As already mentioned, the „low“ pDC 
group had significantly more grade II-IV acute GVHD than the „high“ pDC group. 
The Kaplan-Meier estimate of overall survival was 86% in the „high“ pDC group compared 
to 55% in the low „pDC“ group. This difference stayed significant in the multivariate 
analysis, together with a known factor of worse survival - older age of the recipient. 
Better survival of patients in the „high“ pDC group was mostly due to significantly lower 
cumulative incidence of relapse-related mortality in this group of patients (9% vs 35%).  
Our results indicate that higher number of pDC reconstituted after transplantation may reduce 
relapse and, to our knowledge, we were the first to potentially show the clinical antitumor 
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activity of pDC. However, there have been conflicting resultes published before, as in an 
earlier study by Waller et al.
211 
who associated higher number of pDC with higher rate of 
relapse in transplanted patients. However, there are key differences between this study and 
our observations. The number of pDC evaluated in this study was the number in the graft and 
our results concern the immune reconstitution of pDC in the peripheral blood after 
transplantation. More importantly, most of our patients (70%) received peripheral blood 
instead of bone marrow as stem cell source, and G-CSF administration used to mobilize 
peripheral blood grafts may have changed cytokine release and DC activation status
. 211
  
Rajasekar et al.
117 
hypothesized that graft and early postengraftment DC counts would have an 
important impact on development of acute and chronic GVHD as well. However, they did not 
find a correlation between cell counts in the graft and GVHD, but they found the peripheral 
blood low pDC count on day +28 after allogeneic stem cell transplantation to be an 
independent predictor for both acute and chronic GVHD. Lau et al.
212
 found severity of 
GVHD to be associated with the low mDC and pDC numbers and their activation status. 
As with other analyses, there have been conflicting results as one of the studies
122
 associated 
high pDC number with chronic GVHD, although this was at a median of 14.5 months after 
transplantation. 
In our study, „low“ pDC count was associated with a higher cumulative incidence of 
extensive chronic GVHD (44% vs 30% in the „high“ pDC group) at a median of 20 months 
after transplantation, even though this difference did not reach statistical significance. We 
speculate that the difference was not reached because of the small number of patients with 
extensive chronic GVHD in our study population (12 patients per each pDC group). 
In summary, our findings are in concordance with previous studies and support the role of 
enumerating pDC count at day 100 after allogeneic stem cell transplantation as a simple, fast 
and reproducible indicator of adverse clinical outcome of patients, as relapse, death and 
GVHD. Monitoring pDC count could allow for early classification of patients according to 
the risk for adverse events. This finding would also allow for potential early therapeutical 
interventions or even influencing the pDC number in the blood of patients to improve their 
outcomes. 
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6.5. pDC may have a role in supressing GVHD while promoting GVL effect 
In summary, the results from our study indicate that low pDC count at day +100 after 
allogeneic stem cell transplantation predicts both relapse and higher incidence of GVHD in 
stem cell recipients. 
This finding made us hypothesize about the potential pathophysiological role of pDC in 
supressing GVHD while promoting GVL affect, contrary to the observations with T cells, the 
depletion of which decreases GVHD but increases relapse. 
Two major questions emerge from this hypothesis – pDC chimerism and pDC activation 
status of pDC at day +100 in our patients after allogeneic stem cell transplantation. 
As it has been established before
106
, DC populations in the recipient after transplantation 
represent a combination of residual host DC which have survived the conditioning regimen 
and donor DC which have been infused as part of the graft or have diferentiated from donor 
hematopoietic cell. In a murine model, the presence of host DC is a prerequisite for the 
development of CD8+ T cell-mediated acute GVHD, while donor DC amplify the process. In 
contrast, donor DC seem to be operative in a CD4+ T cell-mediated chronic GVHD, but skin 
chronic GVHD can be induced by host DC as well.
109,213
 
Rapid establishment of full donor chimerism has been observed by day 14 after both 
myeloablative and nonmyeloablative allogeneic stem cell transplantation
214
, but mixed DC 
chimerism and persistence of host DC was detected as well at day +100 after allogeneic stem 
cell transplantation and was correlated with the development of severe acute and chronic 
GVHD.
107 
pDC chimerism was not analysed in our study, due to the rarity of pDC in the peripheral 
blood (<1% of PBMC). However, according to the previous studies, we presume that most of 
our patients had a full donor DC chimerism at day +100 after transplantation. If we assume 
that pDC have migrated to the GVHD target organs, our finding is intriguing because it 
suggests the role of donor pDC in both maintenance of acute GVHD and predicting chronic 
GVHD. 
However, the role of DC in the immune response depends of their activation status, and TLR-
activated pDC secrete high levels of IFN alpha and stimulate CD4+ and CD8+ T cells, while 
in the steady state, pDC have intrinsic tolerogenic properties, induce Tregs and have been 
implicated in the regulation of disease in the experimental models of autoimmunity.
215 
The finding that BDCA2, a pDC specific marker is downregulated upon pDC activation and is 
preserved in our pDC from transplanted patients, might suggest that circulating pDC in our 
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study were in resting state.
124
 This assumption does not contradict the hypothesis that 
activated pDC may have migrated to the activated GVHD tissues. 
Additional mechanisms for a protective impact of circulating pDC against relapse and GVHD 
can be extrapolated from the study of Sato et al.
216
 which suggest the role of immune 
regulatory cells. More precisely, administration of regulatory DC after allogeneic bone 
marrow transplantation protected mice from relapse and acute GVHD, respectively. 
Mechanisms in this model include activating Tregs through DC and supressing the effector 
functions of CD4+ and CD8+ cells. This study also showed that regulatory DC induce a more 
potent tolerance in CD4+ T cells than in CD8+ T cells. CD8+ T cells were previously 
reported to participate in the GVL effect, so they hypothesized that DC-regulated cytotoxicity 
which failed to cause acute GVHD may be sufficient to cause GVL effect.  
In seems possible that activated pDC could have migrated to the acute GVHD target tissues 
but circulating donor pDC in the blood of patients could be in the resting state and could have 
a role in preventing chronic GVHD while supporting GVL effect. However, more functional 
studies are needed to decipher the exact role of pDC in antitumor immunity and GVHD. This 
could especially be done in the RIC setting, where the role and the impact of these rare 
population of immune cells logically tends to be more evident. 
6.6. pDC represent important targets for future therapies 
Current therapeutical approaches in GVHD are targeted against T cells, but given the 
importance of DC in the pathogenesis of GVHD, mDC and pDC represent important targets 
for future therapies.
217
 However, existing therapies already affect DC function. More 
precisely, calcineurin inhibitors (as cyclosporine) supress antigen presentation, corticosteroids 
inhibit DC maturation and activation, while ATG induces complement-mediated lysis of DC 
and decreases their capacity to stimulate allogeneic T cells.
218 
Innovative treatment approaches target DC in vivo and in vitro, latter by producing negative 
DC vaccines or tolerogenic DC in culture conditions by pharmacological modification or cell 
sorting. In vivo DC manipulation comprises of pharmacological interventions which block DC 
maturation, reduce expression of co-stimulatory molecules and cytokine release and decrease 
T-cell allostimulatory capacity. In an experimental setting, anticancer drugs as HDAC 
inhibitors
219
, proteasome inhibitors
220
 and NF-κB221 inhibitors were shown to attenuate 
GVHD while preserving GVL effect. A biologic intervention that has been shown to act in the 
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same way in an experimental model is targeting activated DC by a monoclonal antibody 
against CD83, a cell surface molecule usually upregulated upon DC maturation.
222 
Furthermore, DC can be targeted in vivo by cell therapies which have been shown to have 
immunosupressive properties as well, as mesenchimal stem cells
223
, myeloid-derived 
supressor cells
224
 and T-regs
225
, respectively. 
Importantly, cell therapies have begun in humans and recently a DC based vaccine has been 
approved in treatment of prostate cancer by FDA.
226
 Moreover, a phase I safety study of 
tolerogenic DC in autoimmune diabetes
 227 
is being conducted, as well as many clinical trials 
for the prevention and treatment of GVHD which target DC.
218 
Therefore, our and similar studies are important in further understanding of the precise 
immunoregulatory properties of pDC and pave the way for the new targeted therapies in 
GVHD and hematological malignancies, given the importance of the GVL effect. 
6.7. The reduced number of Th17 in peripheral blood of transplanted patients correlates 
with clinically significant acute GVHD. 
Previous studies established an important role of effector Th1 cells in acute GVHD 
pathophysiology.
 
The identification of proinflammatory Th17 cells which contribute to 
autoimmune diseases, especially inflammatory bowel disease
228 
raised the question of the role 
of Th17 cells in human acute GVHD. However, the contribution of Th17 cells in acute 
GVHD has been explored in humans with conflicting results. Of note, in peripheral blood of 
patients with acute GVHD, Th17 subpopulation of cells was found to be both increased
157
 and 
decreased.
158
 In acute skin GVHD, Th1 and not Th17 cells were found to be significantly 
increased.
158
 In one study Th17 were not found to be significant in the acute intestinal 
GVHD
159
, while in the recent study of our study group
208
 we showed a significant increase of 
Th17 population in the intestinal mucosa of acute GVHD patients.  
In this study we investigated the role of Th17 cells in the peripheral blood of patients at day 
100 after allogeneic stem cell transplantation. Here we observed that patients with grade II-IV 
acute GVHD at day 100 had significantly lower percentages of CD161+ Th cells than patients 
without clinically significant acute GVHD (grades 0-I). 
Our results are in concordance with the recent study of van der Waart et al
229
, who also 
evaluated the count of CD161+CD4+ T-cells as well as CD161+CD8+ T-cells and observed a 
significant decreased frequency in peripheral blood samples 3 months after transplantation in 
patients with acute GVHD. We speculate that the decrease in circulating CD161+ Th cells is 
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due to their specific recruitment into GVHD affected tissues. This is in concordance with the 
results from the previous study
208
 of our study group based on the same group of patients, 
where Th17 cells counts increased in acute GVHD-affected intestinal mucosa. Consequently, 
at day 100 after transplantation these cells may have migrated from the peripheral blood to 
GVHD target tissues in patients with clinically significant acute GVHD. 
The abbility of Th17 cells to migrate to GVHD organs has been associated with the high 
expression of CCR6 on their surface. CCR6 is a chemokine with only one ligand, CCL20, 
which is constitutively expressed in organs such as liver, colon, small intestine and skin.
230
 
Furthermore, damage of the epidermal barrier, as well as stimulation with IL1 alpha and IL1 
beta which are part of the cytokine storm created after conditioning regimen, were shown to 
up-regulate CCL20.
231,232
 All together, these findings support the hypothesis of the pathogenic 
role of CD161+ Th17 cells in the acute GVHD. 
Importantly, we also observed a decrease of CXCR3+ cells at day +100 in the peripheral 
blood of patients with clinically significant acute GVHD, highlighting the role of these cells 
in the acute GVHD pathophisiology. CXCR3+ is a hallmark of IFN gamma secreting and 
most Th1 cells are CXCR3+. However, previous clinical studies have shown that Th17 
phenotype is unstable and that Th17 can convert to Th1 cells 
229 
as well it has been clear both 
preclinically
153
 and clinically
 229
 that, during acute GVHD, IL17A producing cells can also 
coproduce IFN-gamma. By following our previous findings, we can speculate that, in the 
context of GVHD, Th17 cells infiltrate target tissues of acute GVHD, and then either 
conserve their pathologic properties, either convert into a Th1 phenotype. 
In a similar study
157
, Th17 subpopulation increased in the peripheral blood of patients with the 
occurence of acute GVHD, but in patients recovering from GVHD progressively declined 
reaching the levels lower than in the healthy donors. The low proportion of Th17 in these 
patients was explained with a higher proportion of circulating Tregs in patients with inactive 
forms of GVHD.
233
 In a similar context, in our study population, a lower count of CD161+ 
and CXCR3+ Th cells at day 100 after stem cell transplantation could be also in relation to an 
increased Treg population in the controlled GVHD setting. 
6.8. The reduced number of Th17 cells in the peripheral blood of transplanted patients 
at day 100 is an independent predictor of extensive chronic GVHD 
As mentioned before, the pathophisiology of chronic GVHD is poorly understood. In general, 
CD4+Th1 cells were held responsible for the development of acute GVHD and CD4+Th2 for 
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the development of chronic GVHD. However, chronic GVHD manifests with features 
characteristic of autoimmune diseases, including sclerodermatous skin disease, and Th1 
cytokine IFN gamma can clearly play a causal role.
158,234
 Consequently, chronic GVHD does 
not fit easily into either Th1 or Th2 paradigms.
29
 In systemic sclerosis, a condition closely 
resembling scleroderma, the predominant clinical feature of chronic GVHD, fibrosis, is 
mediated by Th17 cells infiltrating the skin and serum IL17 levels positively correlate with 
disease severity.
235,236 
In the setting of chronic GVHD, recent preclinical and clinical data 
support a role for IL17A as a central mediator of pathology, particularly within the skin.
155,157
 
In our study, we hypothesized that number of Th17 cells at day 100 after allogeneic stem cell 
transplantation could serve as a predictor for the development of chronic GVHD. In the 
univariate analysis we found acute GVHD and low Th17 count to be significantly associated 
with the development of extensive chronic GVHD, and observed more extensive chronic 
GVHD in patients who received a transplant from a female donor. The female donor and 
acute GVHD are known risk factors for chronic GVHD, but when we performed a 
multivariate analysis of our data, only a low Th17 count at day +100 after allogeneic stem cell 
transplantation in the peripheral blood of patients retained its predictive value for extensive 
chronic GVHD. 
Our results are in concordance with a previously mentioned study where the association 
between decreased CD 161 expressing cells at 3 months after transplantation and later-on 
chronic GVHD also remained independent from the known confounders such as age, gender 
combination and graft source in the multivariate analysis. 
Therefore, we conclude that enumerating Th17 cells at day +100 after allogeneic stem cell 
transplantation may be a simple, fast, and reproducible method to predict the future 
development of extensive chronic GVHD. By allocating the patients into a „low“ or a „high“ 
Th17 group at this time point after stem cell transplantation, it would potentially be possible 
to stratify the patients into risk groups for developing extensive chronic GVHD. It would also 
become feasible to further stratify them for early therapeutic interventions to enhance or 
negate the impact of chronic GVHD and modify the outcome of the patients. 
6.9. Th17 represent a promising target for the prevention and treatment of GVHD 
Previous animal studies suggested that a combined blockade of Th1 and Th17 differentiation 
pathways of donor T cells may represent a promising strategy for the prevention and 
treatment of GVHD, while inhibition of either pathway alone seems to be 
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insufficient.
156,160,161 
In this context in humans, novel strategies which target Th1 and Th17 
promoting cytokines represent a new, attractive method for the control of GVHD. 
Moreover, cytokine-neutralizing monoclonal antibodies are increasingly being investigated in 
the treatment of patients with cancer and autoimmune diseases. 
Ustekinumab is a monoclonal antibody against p40, a common component of IL-12 and IL-
23, both cytokines important for the differentiation of effector Th1 and Th17 cells. The 
efficacy and safety of ustekinumab has been demonstrated in Phase II studies for multiple 
sclerosis, sarcoidosis and Crohn’s disease237,238 and in Phase III trials for treatment of 
psoriasis.
239-241
 
Furthermore, clinical trials using anti–IL17 monoclonal antibodies are emerging, aiming to 
directly block the Th17 response. Several studies are currently evaluating the IL17 blockade 
in the treatment of psoriasis.
242
 Ixekizumab and secukinumab are human monoclonal 
antibodies to IL17A that were proven to be effective in the treatment of psoriasis in Phase II 
clinical trials
243-245
, while brodalumab binds to IL17RA and is currently studied in the Phase 
III clinical trials so far showing promising clinical improvement in more than 75% of patients. 
246-248
 
Modulation of the Th17/Treg balance by cytokine blockade is another attractive strategy to 
prevent GVHD. Tocilizumab, monoclonal antibody against IL-6R, has been shown to be 
effective against several autoimmune and inflammatory diseases such as rheumatoid arthritis 
and Castleman’s disease.249-251 A hypothesis developed from animal studies suggests that IL-6 
blockade attenuates acute GVHD by shifting Th17 responses toward Tregs. A single case 
report showed the effectiveness of tocilizumab in a patient with refractory gastrointestinal 
acute GVHD.
252
 Furthermore, a recent study demonstrated tocilizumab efficacy for skin 
lesions in patients with systemic sclerosis, suggesting that tocilizumab could also be effective 
for treatment of sclerodermatous skin lesion in chronic GVHD.
253
 
In conclusion, monoclonal antibodies against cytokines important in effector cell pathways 
represent an attractive future perspective for prevention and treatment of GVHD. 
Importantly, in the setting of allogeneic stem cell transplantation, timing of administration of 
anti-cytokine antibodies will be particularly important for cytokine modulation. However, 
reduced intensity conditioning that has been developed to minimize toxicity of conditioning 
regimen will pave the way for the development of such novel strategies. 
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6.10. There is a potential pathophysiological link between decrease of the number of 
pDC in peripheral blood of transplanted patients and the decrease of the number of 
Th17 
The decrease of the number of pDC in the peripheral blood of our patients at day 100 after 
allogeneic stem cell transplantation was paralleled by the decrease of the number of Th17 
cells as well, suggesting a potential pathophysiological link between pDC and Th17 response 
in the context of both acute and chronic GVHD. 
From the pathophysiological standpoint, our findings support a GVHD induction model that 
can mimic data from other autoimmune diseases.
100,254-256 
It has already been shown that the 
induction of Th17-related cytokines is abrogated in pDC-depleted mice.
254 
Moreover, type I 
IFN produced by pDC after stimulation with a TLR7 agonist are able to drive Th17 responses 
in vivo.
257,258
 Therefore we can speculate that activated pDC recruit to GVHD target tissues 
following local damage (e.g. conditioning regimen) and drive the differentiation of Th17 
cells, although the exact mechanism that links type I IFN production to pDC-mediated Th17 
responses remains unclear and needs to be adressed in future. 
However, data described in this paper do not contradict the established role of Th1 cells in 
GVHD pathophysiology, as the decrease of peripheral pDC at day +100 in our study was also 
paralleled by the decrease of peripheral blood CXCR3+CD4+ T cells. Similarly, it has already 
been shown that human Th17 cells may exhibit a close developmental relationship with Th1 
cells.
177
 As Th17 cells can easily convert to a Th1 phenotype, as well as they can coproduce 
IFN gamma, a likely scenario is a synchronized or reciprocal interplay between Th1 and Th17 
as previously reported in autoimmune arthritis.
259
 
It is clear that our study was done retrospectively and the patients' blood samples were frozen 
and then thawed at one time point. Moreover, our study group was rather heterogenous, as for 
diagnosis and transplant characteristics, precluding establishing the definitive role of pDC and 
Th17 after allogeneic stem cell transplantation. Therefore, more prospective studies with more 
homogenous groups of patients are needed. However, our results altogether provide further 
evidence for an important impact of pDC and Th17-mediated responses in human GVHD. 
Moreover, our data raise the prospect of future innovative approaches to optimize 
immunosuppression regimens for the treatment or prophylaxis of GVHD by targeting pDC 
and the Th17 response. 
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6.11. Th1 cytokines and chemokines in peripheral blood of transplanted patients at day 
100 have a pathogenic role for the development of chronic GVHD while Th2 cytokines 
and chemokines have a protective role 
It is widely accepted that Th1 subpopulation and Th1-related proinflammatory cytokines such 
as IFN gamma and TNF alpha are important in the initiation of the acute GVHD. As 
previously mentioned, chronic GVHD does not fit easily into either Th1 or Th2 paradigms 
and its pathophysiology stays poorly understood. It is also known that acute GVHD primarily 
involves the skin, liver, gastrointestinal tract and lymphoid tissues, while chronic GVHD is a 
systemic and multiorgan syndrome that has many features suggestive of a range of 
spontaneous autoimmune diseases. Previous studies with animal models of autoimmune 
diseases have characterized the pathogenic role of Th1 cells and the possible protective role of 
Th2 cells.
260,261
 A recent study in humans examined the expression of cytokines, chemokines 
and chemokine receptors in oral lesions from chronic GVHD patients.
262
 In this study, Th1 
cytokines such as IL2 and IFN gamma were consistently expressed in nearly all of the oral 
lesions examined in chronic GVHD patients, and the degree of such cytokine expression 
showed no relationship to the degree of lymphocytic infiltration or to the clinical severity. In 
contrast, Th2 cytokines such as IL4 and IL5 were expressed in association with strong 
lymphocytic infiltration and severe tissue damage in the oral lesions in chronic GVHD 
patients. These findings suggested that Th1 cytokines might be primarily involved in the 
initiation and/or maintenance of chronic GVHD, while Th2 cytokines are involved in the 
progression of the disease process. 
In our study, we extensively studied 41 cytokine and chemokine at day 100 after 
transplantation and their relation to the development of chronic GVHD after day 100. In the 
multivariate analysis we defined 8 cytokines and chemokines related to the development of 
chronic and 10 cytokines and chemokines related to the development of chronic extensive 
GVHD. IP10, FLT.3L, IL15, IL10 and TNF alpha seemed to increase the chance of chronic 
GVHD,  while FRACTALKINE, MDC and TARC seemed to decrease the chance of chronic 
GVHD. Furthermore, IP10, IL10, IL2ra, MIP1b and IL2 seemed to increase the chance of 
extensive chronic GVHD, while FRACTALKINE, MDC, RANTES, IL12p40 and TARC 
seemed to decrease the chance of extensive chronic GVHD.  
In our study Th1 cytokine IL2 and IL2 receptor alpha (IL2ra) were consistently elevated in 
the serum of patients who developed extensive chronic GVHD, confirming the role of the Th1 
subpopulation in chronic GVHD (p = 0.047 and p = 0.0212, respectively). 
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IL2ra is one of previously validated biomarkers with diagnostic and prognostic value for acute 
GVHD
263
, which was also prospectively evaluated and proven to be a good predictor of 
clinical outcomes as death and nonresponsiviness to therapy. 
264
 Moreover, IL2 production by 
donor T cells remains the main target of many current clinical therapeutic and prophylactic 
approaches for acute GVHD, such as cyclosporine A, tacrolimus and monoclonal 
antibodies.
265,266
 Daclizumab is a humanized monoclonal antibody, which inhibits 
competitively the IL2ra, and has been found to be effective in the second-line treatment of 
refractory acute and chronic GVHD.
267,268
 
As already mentioned, the role for TNF alpha in clinical acute GVHD has been suggested by 
studies demonstrating elevated levels of TNF alpha in the serum of patients with acute 
GVHD.
171
 Target organ damage could be inhibited by infusion of anti TNF alpha monoclonal 
antibodies.
172
 In our study, we confirmed TNF alpha as a valuable indepedent predictor of 
chronic GVHD development (p = 0.02). 
Dose and timing of cytokine production are critical factors with regard to their role in the 
induction of GVHD. This is illustrated by the case of IL10 produced by DC and Th2 cells 
which is critical for the induction of Tregs. Higher production of IL10 or the presence in 
recipients of a polymorphism linked with increased IL 10 production
 
is associated with 
reduced incidence and severity of acute GVHD.
178,179 
Paradoxically, high-serum IL10 levels 
in patients after allogeneic stem cell transplantation are associated with a fatal outcome
180
, 
whereas administration of low doses of IL10 is protective in murine acute GVHD
181
, 
highlighting the pleiotropic, but also opposing, nature of cytokines during the different phases 
of GVHD pathogenesis. In our study IL10 was shown to increase the chance of chronic 
GVHD ( p = 0,03299) . 
Both GVHD and GVL effect depend on T-cell reconstitution after allogeneic stem cell 
transplantation. T-cell reconstitution initially depends on homeostatic peripheral expansion of 
donor T cells, and IL7 and IL15 are known to be key homeostatic cytokines in this process. 
Accordingly, studies which analysed blood levels of these cytokines showed that high levels 
of these cytokines on day 14 after allogeneic stem cell transplantation could positively predict 
the development of acute GVHD, while a reduced level of IL15 was associated with a greater 
risk of malignant relapse.
269
 In our study, the high concentration of IL15 on day 100 after 
allogeneic stem cell tranplantation was also strongly associated with the development of 
chronic GVHD (p = 0,0144) and could therefore be used as a marker of both acute and 
chronic GVHD development. 
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Flt3L is a nonredundant cytokine required for DC homeostasis in lymphoid tissues. In a recent 
study  pretreatment with lymphocyte only transplantation and continued Flt3L treatment with 
sublethal irradiation followed by combined bone marrow and lymphocyte transplantation led 
to full and partial protection from GVHD, respectively. The latter was correlated with higher 
relative host DC, and host and donor Treg numbers after transplantation.
270 
However, this cytokine in our study increased the chance of chronic GVHD development. (p 
= 0.0032). 
IL12 is a heterodimeric cytokine that is composed of two subunits (p35 and p40) and acts to 
promote both NK cell and CTL activity. In addition, IL12 induces undifferentiated Th0 cells 
to commit to the Th1 phenotype and reduces Th2 activity.
271,272
 For this reason, IL12 has been 
tested as an immunotherapeutic agent for the treatment of a variety of Th2-mediated 
diseases.
273-275
 Both anti-IL12 Ab and the homodimeric p40 subunit of IL12 act as IL12 
antagonists and have been used to prevent Th1-mediated diseases.
276,277
 One study showed 
that the use of IL12-encoding plasmid improved Th1/Th2 balance and prevented the 
development of murine chronic renal GVHD, without causing acute GVHD.
278 
Importantly, 
our study also showed that a higher level of this cytokine reduces the incidence of 
development of extensive chronic GVHD (p = 0.0417).
 
In identifying the significant chemokines at day 100 after allogeneic stem cell transplantation, 
our study confirmed most evaluated Th1 chemokines as pathogenic and Th2 chemokines as 
protective for chronic GVHD. 
IP10 is one of chemokines toward CXCR3, has a chemotaxis for monocytes and Th1 cells, 
and is produced by fibroblasts and vascular endothelial cells
279-281
 while CXCR3 and CCR5 
are specific chemokine receptors for Th1 cells.
282,283 
Serum CXCL10 (IP10) was proposed to 
be an accurate marker for the development of acute GVHD.
284
 In our study, we also found 
CXCL10 (IP 10) to be the strongest indepedent marker for the development of chronic GVHD 
as well (p<0,0001). One of the chemokines overexpressed in GVHD target organs
285
 and 
another CCR5 ligand, MIP 1b, was also elevated in the blood of our patients and positively 
predicted the development of extensive chronic GVHD (p = 0.0315) . 
TARC and MDC are natural ligands for CCR4 and serve as chemokines which attract Th2 
cells.
286,287
 TARC is produced by vascular endothelial cells and DC,  while MDC is produced 
by APC.
288,289
 In our study, these chemokines had a protective role for the development of 
both chronic and extensive chronic GVHD (p = 0.0192 and p = 0103 for MDC and p = 0.0438 
and p = 0.0389 for TARC, respectively) and this finding would be consistent with the 
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hypothesis that Th2 subpopulation of lymphocytes has a protective role in the pathogenesis of 
chronic GVHD.  
In murine models, the systemic release of inflammatory cytokines such as TNF alpha and IFN 
gamma by T cells activated within lymphoid tissue leads to the release of the chemokines 
CXCL9-11 at tissue sites.
182
 These recruit CXCR3+ T cells, which are believed to mediate the 
tissue damage characteristic of GVHD. A second wave of T cells that produce CCR5 ligands, 
such as CCL5 (RANTES), is then induced and may play a role in limiting tissue damage.
290 
In our study, higher levels of blood RANTES also seemed to decrease the chance of extensive 
chronic GVHD (p = 0.0214). 
Finally, Fractalkine is the unique ligand for the chemokine receptor CX3CR1, which is 
expressed on monocytes, natural killer cells, T cells, and smooth muscle cells, where it 
mediates functions including migration, adhesion, and proliferation.
291-293
 A pro-inflammatory 
role of this cytokine has been shown in autoimmune diseases, as rheumatiod arthritis
294
 and 
inflammatory bowel disease.
295
 However, in our study higher blood levels of this chemokine 
decreased the chance of extensive chronic GVHD development (p = 0.0214). 
In general, our results suggested that an elevated concentration of Th1 cytokines and 
chemokines at day 100 in transplanted patients could be predictive of chronic GVHD 
development while an elevated serum concentration of Th2 cytokines and chemokines could 
negatively predict the chronic GVHD development. 
6.12. A prognostic score made of the most signficant serum cytokines and chemokines at 
day 100 in transplanted patients can accurately predict the development of chronic 
GVHD and chronic extensive GVHD at 2 years after allogeneic stem cell transplantation 
We next sought to establish a practical prognostic score capable of predicting chronic and 
chronic extensive GVHD. This score was calculated using the traditional multivariate Cox 
model combined with the statistical approach called “time-dependent receiver-operator 
characteristic (ROC) curves. Here, we have focused on the significant clinical variables and 
the most significant cytokines found in the multivariate analysis in order to obtain a useful 
tool in the daily medical practice. Based on 0,632 bootstrap resampling method for repeated 
cross-validation, the area under the time-dependent ROC curve was 0.80 (95%CI, 0.72-0.87) 
for chronic GVHD and 0.78 (95%CI, 0.66-0.88) for chronic extensive GVHD indicating that 
such composite score is a powerful predictor of the risk of GVHD at 2 years. These results do 
not seem exceptional when known that there are studies with ROC curves with AUC between 
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0.9 and 1.0 which give exceptional predictive markers. However, our score is prognostic, 
while the most of the previous scores are diagnostic. The prognostic scores are time 
dependent, which has to be taken into consider when the statistics is done. Also, unlike 
previous studies, our results are more realistic because we kept the „overfitting“ in mind and 
used a bootstrap 0.632 correction. Of course, this score has to be also validated externally. 
Results from this study allowed to build a new noninvasive score to accurately predict the risk 
of chronic and chronic extensive GVHD occurrence after allogeneic stem cell transplantation. 
Such score could be used as a decision tool in the clinical management after allogeneic stem 
cell transplantation.  
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7. Conclusions 
7.1. Acute GVHD is the only independent predictor of impaired blood pDC recovery at 
day 100 after transplantation 
The recovery of pDC in the peripheral blood at day 100 after allogeneic stem cell 
transplantation in our patients was not influenced by the patients' or graft characteristics, 
conditioning regimen or infections, as it has been shown in previous studies. On the contrary, 
in our group of patients, only the occurence of grade II-IV acute GVHD in the multivariate 
analysis was found to be significantly associated with an impaired pDC recovery in the 
peripheral blood at day 100 after allogeneic stem cell transplantation. 
7.2. Corticosteroid therapy downregulates function of activated pDC 
When we excluded patients who at day 100 still received high doses of corticosteroids, blood 
pDC count stayed significantly higher in the acute GVHD group of patients, while activated 
pDC secreted similar amounts of IFN alpha and TNF alpha in both patients with and without 
acute GVHD. This finding suggested that the resting pDC in the blood of patients were 
functionally less activated due to the corticosteroid treatment. This observation is in 
concordance with previous studies where corticosteroids seemed to prevent DC maturation 
and impair their immunostimulatory activities, without affecting their viability. 
7.3. Activated pDC and effector Th17 cells have a pathogenic role in acute GVHD 
Patients with grade II-IV acute GVHD had significantly lower percentages of peripheral 
blood pDC, IFN alpha-secreting pDC and Th17 than patients with grade 0-I acute GVHD. 
This is in concordance with our previous study where we found both of these populations 
increased in the intestinal biopsies of patients with acute GVHD. Our hypothesis is that 
activated pDC and Th17 migrated from peripheral blood to target GVHD tissues. Moreover, a 
decrease of pDC paralleled with the decrease of Th17 could suggest a potential 
pathophysiological link between these two populations in acute GVHD. Our findings support 
earlier studies where pDC seemed to have a role in triggering Th17-related cytokines. 
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7.4. Low blood pDC count at day 100 after transplantation is an independent predictor 
of relapse and overall survival  
By allocating the patients according to the pDC recovery profile  into a „high“ and „low“ 
pDC group, we found significantly better overall survival in the „high“ pDC group of 
patients. Consequently, we presumed a potential „protective“ role of blood resting pDC and at 
the same time we showed significantly higher relapse-related mortality in the „low“ pDC 
group. Therefore, our results also highlighted the clinical antitumor activity of the blood 
resting pDC. In a multivariate analysis, a „high“ pDC count and younger age of patients 
stayed indepedent favorable prognostic factors for longer survival. This is in concordance 
with previous studies and suggests that quantification of pDC at 3 months after transplantation 
could be a simple and useful tool for predicting patients' outcome. 
7.5. Low blood Th 17 count at day 100 after transplantation is an independent predictor 
of chronic extensive GVHD 
By allocating the patients according to the Th17 count into a „high” and „low“ Th17 group 
we found significantly higher cumulative incidence of extensive chronic GVHD in the „low“ 
Th17 group. Moreover, “low” Th17 count stayed the only independent predictor of extensive 
chronic GVHD in the multivariate analysis. This is in concordance with a recent study which 
also showed that decreased CD 161+ cells at 3 months after transplantation can independently 
predict later-on chronic GVHD. Enumerating Th17 cells at day +100 after allogeneic stem 
cell transplantation could therefore be a simple and reproducible method to predict the future 
development of chronic GVHD.  
7.6. Ten serum cytokines at day 100 after transplantation predict the development of 
chronic extensive GVHD 
In accordance with previous studies, our results suggested that elevated concentrations of Th1 
cytokines at day 100 could be predictive of chronic GVHD development while elevated serum 
concentrations of Th2 cytokines could negatively predict chronic GVHD development. More 
precisely, we found 10 cytokines significantly correlated with the incidence of extensive 
chronic GVHD. High levels of IP10 (CXCL10), IL15, IL10, IL2RA and MIP-1beta (CCL4) 
were associated with higher incidence of extensive chronic GVHD, while high levels of 
Fractalkine (CX3CL1), MDC (CCL22), RANTES (CCL5), TARC (CCL17), IL12p40 were 
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associated with a lower risk of developing extensive chronic GVHD. These cytokines could 
serve as potential biomarkers of chronic GVHD development. 
7.7. A noninvasive score derived from serum cytokines levels at day 100 after 
transplantation accurately predicts the development of chronic extensive GVHD 
By focusing on the significant clinical variables and the most significant cytokines at day 100 
after stem cell transplantation, we obtained a useful tool for the daily medical practice. We 
succeeded in making a prognostic blood test for extensive chronic GVHD development, while 
most previous studies evaluated diagnostic tests. AUC of 80% makes our prognostic score a 
powerful predictor of the risk of extensive chronic GVHD at 2 years. An additional validation 
of this score should be done on another independent cohort. 
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8. Summary 
GVHD continues to be a major source of morbidity and mortality following allogeneic stem 
cell transplantation (allo-SCT). Previous studies established the role of Th17 subpopulation of 
lymphocytes and the plasmacytoid dendritic cells (pDC) in the pathophysiology of several 
autoimmune diseases. The aim of this research was to evaluate the role of pDC and Th17 in 
the peripheral blood of patients at day 100 after allo-SCT in acute and chronic GVHD and 
GVL effect. The other aim of the study was to expand the search for chronic GVHD 
biomarkers by validating cytokines in the blood of patients at day 100 after allo-SCT and to 
determine a composite prognostic score for prediction of chronic GVHD. 
This study included peripheral blood mononuclear cells (PBMC) of 79 patients taken at day 
100 after allo-SCT and 152 serums from patients who underwent allo-SCT between 2005 and 
2011 in Centre Hospitalier Universitaire de Nantes, France. For functional analysis of pDC, 
PBMC from 79 blood samples were stimulated with TLR7 and TLR9 ligands in the presence 
of IL-3 over 6 hours, and then stained for surface markers and intracellular cytokines (IFN 
alpha, TNF alpha and IL6). Th17 were evaluated quantitatively on the same PBMC by 
staining for specific surface markers. Forty-one serum cytokine and chemokine was studied in 
all 152 serums using Luminex xMAP technology. 
We observed a significant decrease of total and activated pDC, as well as Th17 and IFN 
gamma producing cells in the blood of patients with grade 2-4 acute GVHD as compared to 
patients with grade 0-1 acute GVHD. After dividing patients into 2 distinct groups, using the 
median value of pDC and Th17, we observed that a low pDC count predicts relapse and worse 
overall survival and low Th17 predicts more extensive chronic GVHD. In the multivariate 
analysis, low pDC count retained it’s predictive value for worse overall survival together with 
the older age of the patients while low Th17 count stayed the only independent predictor of 
extensive chronic GVHD. 
Independently from all relevant clinical factors, 10 cytokines were found to be significantly 
correlated with the development of extensive chronic GVHD. Based on the significant 
cytokines and clinical factors, we established a practical prognostic score using the traditional 
multivariate Cox model combined with“time-dependent ROC curves”. The area under the 
time-dependent ROC curve of 0.80 indicated that such composite score is a powerful 
predictor of the risk of extensive chronic GVHD.  
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In concordance with previous GVHD studies, the significant decrease of both pDC and Th17 
cells in peripheral blood on day 100 after allo-SCT in patients with clinically severe acute 
GVHD could be the result of the migration of these cells to target tissues of GVHD. 
Therefore, this study provides evidence for a potential new pathophysiological link between 
pDC and Th17 in human acute GVHD, and identifies these cells as potential new targets for 
prophylaxis and treatment of GVHD. Moreover, we established pDC and Th17 counts in the 
peripheral blood of patients at day 100 after allo-SCT as valuable predictors of overall 
survival, relapse and chronic GVHD and have proposed that these cells, have an important 
role in both GVHD and GVL effect. Monitoring pDC and Th17 count could allow for early 
classification of patients according to the risk for adverse events and allow for potential early 
therapeutical interventions to improve their clinical outcomes. 
Furthermore, new noninvasive score developed in this study to accurately predict the risk of 
extensive chronic GVHD after allo-SCT could be used as a decision tool in the clinical 
management of allo-SCT.  
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9. Sažetak 
GVHD je vrlo česta komplikacija transplantacije alogenične koštane srži (alo-TKS), i dalje 
povezana uz visoku smrtnost. Prijašnje studije su utvrdile ulogu Th17 populacije i 
plazmacitoidnih dendritičkih stanica (pDC) u mnogim autoimunim bolestima. Cilj ovog 
istraživanja je bio procijeniti ulogu pDC i Th17 u perifernoj krvi bolesnika stoti dan nakon 
alo-TKS, u akutnom i kroničnom GVHD-u te GVL učinku. Također, cilj ove studije je bio 
procijeniti ulogu citokina kao potencijalnih biomarkera za kronični GVHD u krvi bolesnika 
stoti dan nakon alo-TKS kao i načiniti praktičan prognostički skor za pojavu kroničnog 
GVHD-a.  
U ovo je istraživanje uključeno 79 bolesnika kojima su periferne mononuklearne matične 
stanice (PMMC) uzete stoti dan nakon alo-TKS i 152 seruma uzetih stoti dan nakon alo-TKS 
od bolesnika koji su alotransplantirani između 2005. i 2011. u Centre Hospitalier 
Universitaire de Nantes, u Francuskoj. Za analizu funkcije pDC, PMMC izolirane iz 79 
uzoraka krvi, stimulirane su ligandima za TLR7 i TLR9 receptore u prisutnosti IL3 kroz 6 
sati, a potom bojane za površinske markere i unutarstanične citokine (IFN alfa, TNF alfa i 
IL6). Th17 su kvantitativno određene na istim uzorcima bojanjem na specifične površinke 
markere. Četrdeset i jedan citokin i kemokin je određivan u serumu 152 bolesnika korištenjem 
Luminex xMAP tehnologije. 
Primijetili smo značajno smanjenje aktiviranih pDC, Th17 te stanica koje proizvode IFN 
gama u bolesnika koji su stoti dan nakon alo-TKS imali razvijen akutni GVHD stadija II-IV u 
odnosu na bolesnike bez ili sa stadijem I akutnog GVHD-a. Kada smo bolesnike podijelili u 
dvije skupine, uzimajući kao razdjelnicu medijan vrijednosti postotka pDC i Th17, primijetili 
smo da niže vrijednosti pDC u krvi predviđaju relaps i lošije ukupno preživljenje bolesnika, a 
niže vrijednosti Th17 predviđaju razvoj ekstenzivnog kroničnog GVHD-a. U multivarijatnoj 
analizi, niže vrijednosti pDC su zadržale prediktivnu vrijednost za lošije preživljenje 
bolesnika, kao i starija dob bolesnika, dok su niže vrijednosti Th17 bile jedini neovisni 
čimbenik za predviđanje ekstenzivnog kroničnog GVHD-a. Deset se citokina, neovisnih o 
važnim kliničkim faktorima, pokazalo značajnima za razvoj ekstenzivnog kroničnog GVHD-
a. Pomoću značajnih citokina i kliničkih čimbenika, stvorili smo praktičan prognostički skor 
na temelju Coxove multivarijatne analize i vremenski ovisnih ROC krivulja. Prema AUC 
vrijednosti od 0.8, radi se o relativno moćnom predskazatelju rizika ekstenzivnog kroničnog 
GVHD-a. 
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U skladu s našom prijašnjom studijom uloge pDC i Th17 u GVHD-u, značajno sniženje ovih 
populacija stanica stoti dan u perifernoj krvi bolesnika s teškim akutnim GVHD-om bi moglo 
označiti migraciju aktiviranih stanica u ciljna tkiva GVHD-a. U svakom slučaju, istovremeno 
značajno sniženje broja obiju populacija u krvi bolesnika može ukazivati na njihovu 
povezanost u patofiziologiji GVHD-a, te ih identificirati kao potencijalne nove ciljne 
molekule u profilaksi i liječenju GVHD-a. Također, utvrdili smo da su brojevi ovih stanica u 
perifernoj krvi stoti dan nakon alo-TKS vrijedni prediktori za ukupno preživljenje, relaps i 
kronični GVHD, te tako pretpostavili da ove stanice imaju značajnu ulogu i u GVHD-u i 
GVL-u. Monitoriranje broja ovih stanica bi moglo omogućiti klasifikaciju bolesnika prema 
riziku za razvoj neželjenih događaja te potencijalnu ranu terapijsku intervenciju za 
poboljšanje njihovog kliničkog ishoda. Novi prediktivni skor za razvoj kroničnog 
ekstenzivnog GVHD-a mogao bi postati vrijedan alat u kliničkom odlučivanju nakon alo-
TKS.  
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